THE TUMOR MICROENVIRONMENT: INSIGHT INTO FIBROBLASTS PATHOPHYSIOLOGICAL FUNCTIONS

Settore Scientifico Disciplinare BIO/10

Dottoranda
Dott.ssa Santi Alice

Tutore
Prof. Cirri Paolo

Coordinatore
Prof. Dello Sbarba Persio

Anni 2011/2013
# TABLE OF CONTENTS

## ABBREVIATIONS

1

## INTRODUCTION

4

### TUMOR INITIATION AND PROGRESSION

4

### THE HALLMARKS OF CANCER CELLS

6

### THE TUMOR MICROENVIRONMENT

9

#### FIBROBLASTS

10
- Activated fibroblasts
- Cancer-associated fibroblasts
- The role of CAFs in cancer initiation and progression

#### ENDOTHELIAL CELLS

17

#### PERICYTES

18

#### IMMUNE/INFLAMMATORY CELLS

18

#### HYPOXIA IN THE TUMOR MICROENVIRONMENT

20

#### ACIDOSIS IN THE TUMOR MICROENVIRONMENT

22
- Carbonic Anhydrases
- Membrane transporters

## THE INTERCELLULAR COMMUNICATION

30

### STRUCTURE AND BIOGENESIS OF EXTRACELLULAR MEMBRANE VESICLES

32
- Exosomes
- Microvesicles

### FUNCTIONS OF EXTRACELLULAR MEMBRANE VESICLES

39
- EMVs in tumor diseases
- Other functions of EMVs

## MATERIALS AND METHODS

47

### CELL CULTURES

47

### MATERIALS

47

### PROLIFERATION ASSAY

48

### FLUORESCENCE ANALYSIS OF PROTEIN TRANSFER

48

### ANALYSIS OF LIPID TRANSFER

48

### CONDITIONED MEDIA PREPARATION

49

### ACIDIFICATION ASSAY

49

### CELL DEATH DETERMINATION

49

### IN VITRO 2D TUMOR MIGRATION ASSAY

49
<table>
<thead>
<tr>
<th>Table of contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>In vitro 3D Tumor Migration Assays</strong></td>
<td>49</td>
</tr>
<tr>
<td>Cocultures separation</td>
<td>50</td>
</tr>
<tr>
<td>Analysis of CA IX expression</td>
<td>50</td>
</tr>
<tr>
<td>Purification of membrane vesicles secreted by CAFs</td>
<td>51</td>
</tr>
<tr>
<td>Dynamic Light Scattering Analysis</td>
<td>52</td>
</tr>
<tr>
<td>Sodium [14C] Bicarbonate Incorporation</td>
<td>52</td>
</tr>
<tr>
<td>[14C] L-Amino Acids Incorporation</td>
<td>52</td>
</tr>
<tr>
<td>GC-MS Measurements</td>
<td>52</td>
</tr>
<tr>
<td>Sample preparation and 2D Electrophoresis</td>
<td>53</td>
</tr>
<tr>
<td>Densitometric analysis of radiolabeled protein spots</td>
<td>54</td>
</tr>
<tr>
<td>In-gel digestion and MALDI-TOF analysis</td>
<td>54</td>
</tr>
<tr>
<td>Capillary-LC-µESI-MS/MS</td>
<td>56</td>
</tr>
<tr>
<td>Cluster Analysis</td>
<td>56</td>
</tr>
<tr>
<td>Small interfering RNA (siRNA) Transfection</td>
<td>57</td>
</tr>
<tr>
<td>Xenograft experiments</td>
<td>57</td>
</tr>
<tr>
<td><strong>The Effect of CA IX Catalysis Products Within Tumor Microenvironment</strong></td>
<td>58</td>
</tr>
<tr>
<td><strong>Aim of the Study</strong></td>
<td>58</td>
</tr>
<tr>
<td><strong>Results</strong></td>
<td>60</td>
</tr>
<tr>
<td>Cancer cells proliferation within tumor microenvironment</td>
<td>60</td>
</tr>
<tr>
<td>Bicarbonate ion contributes to cancer cells proliferation</td>
<td>63</td>
</tr>
<tr>
<td>The role of stromal cells CA IX in promoting cancer cells growth</td>
<td>66</td>
</tr>
<tr>
<td>Cancer cells migration within tumor microenvironment</td>
<td>68</td>
</tr>
<tr>
<td><strong>Discussion</strong></td>
<td>72</td>
</tr>
<tr>
<td><strong>New Concepts About Fibroblasts Trophic Function</strong></td>
<td>76</td>
</tr>
<tr>
<td><strong>Aim of the Study</strong></td>
<td>76</td>
</tr>
<tr>
<td><strong>Results</strong></td>
<td>78</td>
</tr>
<tr>
<td>Fibroblasts transfer proteins and lipids to surrounding cells</td>
<td>78</td>
</tr>
<tr>
<td>Identification of the proteins transferred from CAFs to tumor cells</td>
<td>82</td>
</tr>
<tr>
<td>The role of extracellular membrane vesicles in fibroblasts-tumor cells communication</td>
<td>87</td>
</tr>
<tr>
<td><strong>Discussion</strong></td>
<td>91</td>
</tr>
<tr>
<td><strong>References</strong></td>
<td>95</td>
</tr>
</tbody>
</table>
ABBREVIATIONS

2DE, 2D electrophoresis
AEs, anion exchangers
APCs, antigen-presenting cells
ARF6, ADP-ribosylation factor 6
ASCs, adipose tissue-derived stem cells
ATP, adenosine triphosphate
BCA, bicinchoninic acid
b-FGF, basic fibroblasts growth factor
BTs, bicarbonate transporters
CAF\(_S\), cancer-associated fibroblasts
CAs, carbonic anhydrases
CCL, CC chemokine ligand
CFDA-SE, Carboxyfluorescein diacetate succinimidyl ester
CFPs, circulating population of fibroblasts precursors
CPM, counts per minute
CSCs, cancer stem cells
CXCL, chemokine (C-X-C motif) ligand
DCs, dendritic cells
DMEM or DME, Dulbecco’s Modified Eagle’s Medium
DTT, dithiothreitol
ECM, extracellular matrix
ECs, endothelial cells
ED-A, extra-domain A
EGF, epidermal growth factor
EMM-PRIN, extracellular matrix metalloproteinases inducer
EMT, epithelial-mesenchymal transition
EMVs, extracellular membrane vesicles
EndMT, endothelial-mesenchymal transition
ERK, extracellular signal regulated kinase
ESCRT, endosomal sorting complex required for transport
FAP, fibroblasts activation protein
FBS, fetal bovine serum
FGF, fibroblasts growth factor
FSP1, fibroblasts specific protein 1
GAPDH, glyceraldehyde-3-phosphate dehydrogenase
GLUT, glucose transporters
HDFs, human dermic fibroblasts
HGF, hepatocyte growth factor
HIF-1, hypoxia-inducible factor 1
HPFs, human prostatic fibroblasts
HSCs, hematopoietic stem cells
ICAM, intercellular cell adhesion molecule
IFN, interferon
IGF, insulin growth factor
IL, interleukin
ILVs, intraluminal vesicles
IMG, intussusceptive microvascular growth
LFA-1, lymphocyte function-associated antigen 1
LOX, lysyl oxidase
LPS, lipopolysaccharide
MCP-1, monocyte chemoattractant protein 1
MCTs, monocarboxylate transporters
MDCs, myeloid dendritic cells
MDSCs, myeloid-derived suppressor cells
MFs, myofibroblasts
MHC, major histocompatibility complex
MLCK, myosin light-chain kinase
MMPs, matrix metalloproteinases
MMT, mesenchymal-mesenchymal transition
MSCs, bone marrow-derived mesenchymal stem cells
MVBs, multivesicular bodies
MVss, microvesicles
NBCs, Na+/HCO₃⁻ cotransporters
NDCBE, electroneutral Na⁺-driven Cl⁻/HCO₃⁻ exchanger
NHE, Na⁺/H⁺ exchanger
NK, natural killer
NSF, N-ethylmaleimide-sensitive factor
PARs, protease-activated receptors
PBS, phosphate-buffered saline
PC3-GFP, green fluorescent protein (GFP)-expressing PC3 cells
PCP, planar cell polarity
PDCs, plasmacytoid dendritic cells
Abbreviations

**PDGF**, platelet-derived growth factor
**PG**, proteoglycan
**pHe**, extracellular pH
**pHi**, intracellular pH
**PI3K**, phosphatidylinositol 3-kinase
**PKM1**, pyruvate kinase M1 isoform
**PKM2**, pyruvate kinase M2 isoform
**PLD**, phospholipase D
**pO₂**, oxygen pressure
**PVDF**, polyvinylidene difluoride
**ROS**, reactive oxygen species
**SDF-1**, stromal cells-derived factor 1
**SNAP**, soluble NSF-attachment protein
**SOD-2**, superoxide dismutase 2 (mitochondrial isoform)
**SP**, signal peptide
**SSC**, squamous cell carcinoma
**TAMs**, tumor-associated macrophages
**TF**, tissue factor
**TGF-β**, transforming growth factor-β
**TNF**, tumor necrosis factor
**Treg**, regulatory T cells
**uPA**, urokinase-type plasminogen activator
**V**, relative spot volume
**V-ATPase**, vacuolar proton pump ATPase
**VEGF**, vascular endothelial growth factor
**α-SMA**, α-smooth muscle actin
INTRODUCTION

TUMOR INITIATION AND PROGRESSION

Tumors are genetic diseases that arise through a multi-step process in which the accumulation of mutations occurs mainly in genes involved in cell proliferation and differentiation or in cell death. To date, there are two different theories whose aim is to explain how a cell can collect the number of genetic changes needed to convert its normal phenotype into malignant.

The first hypothesis, initially move by Loeb et al. in 1974, originated from the observation that some tumors had multiple alterations compared to non-transformed tissues both in the karyotype (aneuploidy, translocations or rearrangements of chromosomes) and in nucleotide composition (deletions, insertions and substitutions of single nucleotides), which, it was thought, can not be explained by the normal mutation frequency. Therefore, Loeb et al. proposed the mutator phenotype theory, according to which genetic alterations in cancer cells occur more frequently than in normal ones [1, 2]. The difference in mutation rate was associated with cancer genetic instability due to alterations in genes encoding proteins responsible for the control of DNA replication and/or repair, as well as involved in chromosome segregation, in checkpoints surveillance during cell cycle, in cellular balance between death and birth, and in maintenance of CpG-island methylation patterns [2, 3]. In this hypothesis, genetic instability is responsible for the genotypic heterogeneity, characteristic of the tumor mass and represents the driving force of carcinogenesis [4].

The theory of the mutator phenotype in cancer was first re-examine by Nowell in 1976, who added the concept of clonal evolution to that of genetic instability [5], and then argued by Bodmer and Tomlinson in mid-nineties, which suggest that natural selection has a more important role with respect to genetic instability in tumor initiation and progression. This hypothesis derives from the observation that chromosomal or nucleotide instability is not a common feature of all cancers and is not a conditio sine qua non in tumorigenesis [6, 7]. On the contrary, it is widely accepted that tumor growth is a form of evolutionary process: through the mechanism of natural selection, only the cell carrier of one or more advantageous mutations is able to evade anti-growth signals and the result is an uncontrolled proliferation; after that other random genetic changes occur, each followed by waves of selection and expansion of most suitable clones. This process, together with the high rate of cell turnover, could explain the multiple alterations characteristic of
some cancers. The expression in the malignant cells of a mutator phenotype can, however, promote tumor progression, making it faster [6, 7]. To date, it is not clear whether the genetic instability is cause or consequence of tumorigenesis. In contrast, the hypothesis of natural selection and clonal evolution is validated and it is thought that this process has an important role in establishing the behavioral and morphological heterogeneity of cancer cells [8, 9].

In the last 30-40 years, many studies have suggested that the high heterogeneity of tumor mass can also reflect the hierarchical organization of stem/progenitor cells system, without necessarily excluding the stochastic model of clonal evolution [10]. In cancer of hematopoietic system, brain, breast and prostate have been identified biologically distinct populations of “tumor initiating cells”, which have a similar behavior to stem cells of normal tissue, and for this reason are also known as cancer stem cells (CSCs) [11-15].

The properties that characterize normal stem cells are an extended, often unlimited proliferative potential, the high telomerase activity and the self-renewal ability through both a symmetric cell division (i.e. both daughter cells maintain the properties of progenitor) and asymmetric one (i.e. a daughter cell retains stem cells properties, while the other one begins the differentiation process which leads to the formation of a progeny capable of expressing different functional mature phenotypes). According to these abilities, the role of the CSCs can be identified in three interconnected contexts: by symmetric and/or asymmetric division they produce the heterogeneous population of malignant cells within a primary tumor, form the drug-resistant stem cells niche responsible for relapses following chemotherapy-induced remission and generate metastasis. It was hypothesized that CSCs arise from genetic changes in normal stem cells, or from progenitors, that, for definition, are provided with a significant replicative capacity, but regain self-renewal property after mutations [16-19].

Therapeutic strategies specifically directed to CSCs are considered the only ones able to eradicate the disease by reducing the risk for relapse and metastasis [10].

*Figure I* shows an overview of cancer development, where none of the theories mentioned above is excluded.
The hallmarks of cancer cells

Cancers expand as clones from individual transformed cells and are diseases in continuous evolution due to the process of tumor progression, which generates subpopulations with increasing aggressiveness [20]. Tumor progression, in fact, consists in the progressive loss of aggressiveness due to morphological and metabolic alterations of tumor cells and is the result of several mechanisms (such as changes in gene expression, inactivation of tumor suppressor genes or activation of oncogenes) caused by chromosomal abnormalities, point mutations and an aberrant status of DNA methylation [20-22].

The accumulation of multiple alterations leads transformed cells to acquire characteristics and properties typical of malignancy by providing a competitive advantage compared with their normal counterpart. The new functional capabilities showed by most (if not all) cancer cells include: growth factor-independent proliferation, evasion of anti-growth signals, resistance to apoptosis, unlimited...
proliferative potential, induction of neoangiogenesis, tissue invasion and metastasis [23-24] (Figure I).

In normal tissue, cell proliferation is a controlled event, strictly balanced through anti-proliferative signals, or induction of programmed cell death in order to ensure the cell number required to maintain the correct tissue architecture and thus its function. Cell proliferation is promoted by an exogenous paracrine signal (growth factor), that binds and activates a specific cell surface receptor (mainly with intrinsic tyrosine kinase activity), which, in turn, triggers the intracellular signaling pathway. In contrast, anti-proliferative signals block cell growth by leading somatic cells to a quiescent state, thereby ensuring a homeostasis of cell number, or in a state of post-mitotic irreversible arrest corresponding to the acquisition of a functional phenotype [23]. The activation of apoptotic machinery, instead, occurs in detrimental or stress conditions, such as DNA damage, hypoxia, or survival factors shortage, thus preventing tumor initiation [25]. A further proliferative barrier typical of normal cells is the senescence [26], a process related to telomeres shortening due to the inability of DNA polymerase to replicate these chromosomonal regions during S phase of the cell cycle and because of lack of telomerase gene expression, a specialized DNA polymerase able to perform this action. In fact, normal cells can replicate only a limited number of times and, when exhaust the telomeric region, enter into a non proliferative but viable condition until reaching crisis state and subsequent death by apoptosis [24].

Unlike their normal counterpart, tumor cells proliferation is mainly autonomous and decoupled from external mitogenic signals (Figure I). This independence can be acquired through multiple ways: tumor cells become able to synthesize growth factors for which express specific receptors (autocrine stimulation) [27], overexpress a particular receptor becoming more responsive to the normal concentration of ligand [27], express constitutively activated surface receptors [27] or integrins (receptors that mediate cell-matrix and cell-cell contact) that promote cell survival and growth [28, 29], and have an aberrant regulation of Sos-Ras-Raf-MAPK cascade which continues to transmit an intracellular mitogenic signaling also in absence of normal upstream stimulatory signals [30]. The result is that tumor mass size increase depends on growing number of malignant cells that divides in a unit of time. They, in fact, besides acquiring the ability to sustain chronic proliferation, are capable to circumvent antigrowth signals (Figure I), principally deregulating the two canonical suppressor of proliferation: RB protein (retinoblastoma-associated), which controls the entry into cell cycle especially depending on extracellular signals [31-33] and p53, which arrest the cell in G1/S phase of the cell cycle if DNA is damaged,
if nucleotide pool are depleted, or if nutrient are suboptimal, and elicit apoptotic program when stress condition continues [24]. The mutations that impair p53 function [34, 35] together with the increased expression of apoptosis inhibitors (Bcl-2, Bcl-xL), the down-regulation of pro-apoptotic factors (Bax, Bim and Puma) and the activation of phosphatidylinositol 3-kinase (PI3K)-Akt survival pathway belong also to the strategies that enable cancer cells to escape programmed cell death [24, 25].

In addition to uncontrolled growth and resistance to apoptosis, tumor cells show an unlimited replicative potential mainly (in 85-90% of cases) thanks to telomerase gene up-regulation [36] or in a smaller number of cases by a recombination-mediated mechanism, termed ALT (alternative lengthening of telomeres) [37] (Figure I). The acquisition of these biological traits makes tumor cells capable of giving rise to macroscopic tumors, sometimes visible to the naked eye.

Similarly to what happens during embryogenesis, wound healing or female reproductive cycling, the formation of these cancer masses is accompanied by the growth of new blood vessels [38-40] (Figure I). In fact, like normal tissue, tumors require nutrients and oxygen supplies as well as the elimination of metabolic waste and carbon dioxide [24].

The formation of new blood vessels (termed angiogenesis) is turned on by a process called “angiogenic switch”, which surprisingly occurs during the early stages of neoplastic progression when the balance between pro- and anti-angiogenic factors shifts towards a pro-angiogenic outcome [39] (Figure II). Among the most common strategies used to move this balance there are the up-regulation of vascular endothelial growth factor-A (VEGF-A) [41-43] and/or fibroblasts growth factor (FGF) [44], which stimulate endothelial cells (quiescent in normal adult tissue) to continuously form new vessels, and the down-regulation of trombospondin 1 (TSP-1) [45] or β-interferon, whose role is to inhibit angiogenesis [46, 47]. The results are a vasculature convoluted and tortuous, and vessels enlarged, with an abnormal structure that cause disturbed blood flow [48, 49].

In addition to fulfill metabolic and proliferative needs of tumor cells, the new vessels represent one of the means by which such cells escape from primary tumor and colonize other parts of the body giving rise to metastasis (Figure I). This multistep process begins with the detachment of transformed cells from the extracellular matrix at the site of the primary tumor, follows with the intravasation into nearby vessels, the dissemination into the bloodstream, both directly from the venous capillary and indirectly via lymphatic system, and with the passage through blood vessels wall into the parenchyma of the secondary site where metastasis will grow.
Introduction

[50, 51]. Invasion and metastasis are the typical characteristics of malignancy, in fact, colonization by tumor cells of distant tissues is the cause of 90% of human cancer deaths [52]. These properties are obtained by tumor cells thanks to the loss of expression or mutations of E-cadherin gene, a key factor of cell adhesion [53-55], or of gene encoding other mediators of cell-cell or cell-matrix contact and/or the up-regulation of genes encoding proteins involved in cell migration, such as N-cadherin [55]. During invasion and metastasis processes, epithelial transformed cells activate the epithelial-mesenchymal transition (EMT) program, which leads to assume a mesenchymal phenotype characterized by increased migratory capacity, by high resistance to apoptosis, by an elongated, spindle-shaped morphology, by the expression of matrix-degrading enzymes [56-60] and by the acquisition of stem cell-like capability of self-renewal [61]. Invasion and metastasis are complex processes completed only by transformed cells that present every hallmark described above [23].

**The Tumor Microenvironment**

Solid tumors are complex tissues composed not only of highly heterogeneous cancer cells but also of abundance cellular and non-cellular components, also known as tumor microenvironment, that play an important role in cancer initiation, growth and progression (Figure II). The cellular elements include both cells normally present in the parenchyma tissue or migrated as a result of tumorigenesis, such as fibroblasts, endothelial cells and pericytes, and a plethora of immune/inflammatory cells mostly recruited from circulation or bone marrow, in particular T- and B-cells, macrophages, neutrophils, mast cells and other bone marrow-derived cells [62] (Figure II). These two groups of cells are responsible for the synthesis of the variety of molecules representing the non-cellular components of tumor-associated stroma, such as the extracellular matrix (ECM) proteins, proteases, cytokines and growth factors.

Other elements capable to affect the behavior of malignant cells are extracellular pH, oxygen (O₂) concentration, tissue pressure and fluid flow, also these physical and chemical parameters belong to the non-cellular components of tumor microenvironment [63] (Figure II). The structure and the composition of TM are highly variable, with differences seen among various types of cancer, often in different areas of the same tumor and between patients [64]. Cancer cells can remodel the traits of microenvironment during disease progression, in turn, tumor-associated stroma not only functions as a supporting “scaffold” but also actively
participates to tumorigenesis contributing to the development and expression of certain hallmark capabilities [24, 65-67].

**Figure II. The tumor microenvironment.** Tumor cells acquire the capabilities to resist cell death and to avoid immune destruction, but tumor growth is also promote by the other cellular components of tumor microenvironment. TAMs support growth, angiogenesis and invasion, by secreting numerous pro-tumorigenic proteases, cytokines and growth factors (such as EGF). MDSCs and T\textsubscript{reg} cells, mobilized into the circulation by various cytokines (as TGF-β, and CXCL5-CXCR2), disrupt immune surveillance. CAFs, activated by tumor-derived factors (as TGF-β, FGF or PDGF), secrete ECM proteins and basement membrane components, modulate immune responses, support angiogenesis. Other extracellular elements contribute to tumor progression, including low O\textsub{2} tension, high interstitial fluid pressure and change in specific constituents of the ECM. EndMT, endothelial-mesenchymal transition; Ag, antigen; TAMs, tumor-associated macrophages; CAFs, cancer-associated fibroblasts; MDSCs, myeloid-derived suppressor cells; T\textsub{reg}, regulatory T cells; EGF, epidermal growth factor; TGF-β, transforming growth factor; PDGF, platelet-derived growth factor [68].

**Fibroblasts**

**Activated fibroblasts**

Fibroblasts are the most abundant cellular elements in connective tissue and with the fibrillar ECM, within they are embedded, form the structural scaffolding of organs. These cells are morphologically well described, they have an elongated shape and a typical fusiform or spindle-like profile; but not molecularly characterized, so are identified for what they are not: vascular, epithelial and inflammatory cells [69] (Figure III).

Fibroblasts have multiple roles: they synthesize many of the constituents both of fibrillar ECM (such as type I, type III and type V collagen, and fibronectin) [70, 71] and of basal lamina (for example type IV collagen and laminin) [72]; are responsible for the remodeling and turnover of ECM by secreting matrix metalloproteinases (MMPs) [72, 73]; regulate differentiation and homeostasis of adjacent epithelia
through the secretion of growth factor or other soluble molecules involved in mesenchymal-epithelial interactions [74]; are important participants in inflammatory response to tissue damage and in wound repair [70, 75]. When tissue injury occurs, healing fibroblasts invade the wound and proliferate faster than normal ones both in order to replace lost or damaged fibroblasts due the injury, and to increase its number facilitating tissue repair [76]. Moreover, fibroblasts secrete increased amounts of ECM constituents and MMPs, and generate larger contraction forces promoting wound closure [77]. Healing fibroblasts, also known as myofibroblasts (MFs), are characterized by an “activated” phenotype [78, 79]. They acquire contractile stress fibers, de novo express α-smooth muscle actin (α-SMA) and the alternatively spliced fibronectin isoform containing the extra-domain A (ED-A), and are connected to each other by gap junctions [70] (Figure III). To support the intense production of ECM components, activated fibroblasts possess a dispersed chromatin form (euchromatin) with one or two nucleoli in the nucleus, rough endoplasmic reticulum and a well developed Golgi apparatus [69].

**Figure III. Fibroblasts activation.** Normal fibroblasts are embedded within the fibrillar ECM of the connective tissue, have a fusiform shape, a prominent actin cytoskeleton and vimentin intermediate filaments. Activated fibroblasts (or MFs) differ morphologically and functionally from the quiescent ones. In response to mechanical tension, activated fibroblasts acquire stress fibers, express α-SMA and ED-A splice variant of fibronectin, in addition, form cell-cell contacts through gap junctions. Considering that “tumors are wound that do not heal”, CAFs share several similarities with MFs. Once activated, CAFs produce proteases, growth factors, cytokines and enzymes. FN, fibronectin; FSP1, fibroblasts specific protein 1; FAP, fibroblasts activation protein [modified from ref. 149].

Fibroblasts activation is induced by various stimuli derived from injured epithelia cells, which secrete transforming growth factor-β (TGF-β), epidermal growth factor (EGF) and basic-fibroblasts growth factor (b-FGF), otherwise they can be activated by direct cell-cell contact and communication with leukocytes [80, 81].
The transition from quiescent fibroblasts to activated ones is reversible, in fact, when the stimulus is turned off the number of MFs decreases and the site, now healed, is repopulated of resting fibroblasts with a normal phenotype [69, 77] (Figure III).

Fibroblasts not only are the main cellular element of normal stroma, but also represent the most prominent cell type within reactive stroma of many solid tumors, as breast, prostate and pancreatic carcinoma [82, 83] (Figure II). Peritumoral fibroblasts, also known as cancer-associated fibroblasts (CAFs) [84, 85], have a phenotype similar to healing fibroblasts (including the expression of α-SMA and of ED-A fibronectin), but, unlike them, persist in the activated state. For this reason, tumors are considered as “wounds that do not heal” [86] (Figure III).

Cancer-associated fibroblasts

Heterogeneous subpopulations of fibroblasts has been observed in the margins and infiltrated in tumor mass. They are not always easy identified, because express several markers in common with other stromal cellular elements [82] and only partially share the expression of known markers of the activated state, as α-SMA, fibroblasts specific protein 1 (FSP1), platelet-derived growth factor (PDGF) receptor β and fibroblasts activation protein (FAP) [87, 88]. This heterogeneity may in part reflect the multiple origins of CAFs. At a glance, the predicted sources of CAFs are fibroblasts resident in the tumor site [89] (Figure IV). In fact, within tumor microenvironment, cancer cells secrete numerous growth factors (TGF-β, PDGF and b-FGF), cytokines and chemokines that, through specific receptors present on local fibroblasts surface, trigger various tumor-promoting pathways. As result of this process, commonly called mesenchymal-mesenchymal transition (MMT), fibroblasts increase the production of ECM components, pro-angiogenic factors, chemokines and interleukins [90, 91].

Alternative sources of CAFs are bone marrow-derived mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), and adipose tissue-derived stem cells (ASCs) (Figure IV). MSCs are able to differentiate into mesenchymal tissue cells as bone, fat, cartilage, muscle and fibroblasts [92, 93], in fact, they are recruited to damaged sites during tissue repair, inflammation and to the tumor stroma in different cancer types, as breast, pancreatic and ovarian adenocarcinoma [94-98]. MSCs, recruited to the tumor site, thanks to growth factor (as VEGF, EGF, hepatocyte growth factor or HGF, b-FGF and PDGF) and cytokines (as monocyte chemoattractant protein 1, MCP-1, also known as CC chemokine ligand 2, CCL2)
secreted by cancer cells or by reactive stroma, differentiate into pericytes, MFs and endothelial cells contributing to the CAF populations [99-102].

HSCs, instead, are able to give rise to all functional blood cells and are precursors of osteoclasts and mast cells. Recent studies showed that a circulating population of fibroblasts precursors (CFPs) derived from HSCs are present in tumor mass. Their recruitment is mainly mediated by MCP-1 and by stromal cells-derived factor 1 (SDF-1), also known as chemokine (C-X-C motif) ligand 12 (CXCL12) [103]. The transition of HSCs-derived CFPs to the activated phenotype is mediated by TGF-β [104-106].

The signaling pathway triggers by TGF-β has an important role also in the activation of ASCs, which are able to give rise to CAF-like cells when treated with conditioned media from breast cancer cell lines [107].

Another proposed sources of CAFs are cells of epithelial origin and endothelial cells, which, respectively through EMT [82, 108] and endothelial-mesenchymal transition (EndMT) [109], acquire fibroblasts morphology and express high levels of α-SMA [109, 110] (Figure IV). Similarly, CAFs can stem directly from carcinoma cells through EMT, which enhances their migration and invasion ability [82, 108, 111] (Figure IV). Finally, pericytes, i.e. cells present within the basement membrane of

---

**Figure IV. Multiple origins of CAFs within tumor microenvironment.** CAFs can derive from resident fibroblasts through MMT, from MSCs, HSCs, ASCs, and pericytes. Alternatively, CAFs can stem from epithelial and cancer cells through EMT, or from endothelial cells through EndMT [modified from ref. 115-116].
capillaries and post-capillary venules often located closer to the tumor site, are another plausible source of CAFs [112, 113] (Figure IV).

The precursors of CAFs pool of reactive stroma can vary with tumor type, during its progression and in the different areas of the same tumor. Considering the multiple origins suggested and the difficulty of identifying specific markers, Madar et al. had recently proposed a new definition for CAFs, as a cell “state” rather than a cell type. In other words, cells of different origins can exhibit CAFs state, which is a dynamic condition of fibroblasts-like cells acquired in the vicinity of tumor microenvironment, that actively promote cancer progression [114].

The role of CAFs in cancer initiation and progression

The activation of fibroblasts is mediated by numerous growth factors and cytokines secreted by cancer cells, such as TGF-β [117], PDGF-α/β [118, 119], b-FGF [120] and interleukin (IL) -6 [121] (Figure V). In turns, altered fibroblasts are able to promote tumor initiation, its progression and metastasis.

The direct involvement of fibroblasts in cancer initiation was demonstrated by using mouse as xenograft model organism. In this context, Olumi et al. showed that immortalized epithelial cells, co-injected into mice with CAFs obtained from the primary tumor site, form cancerous masses, on the contrary, this effect does not occur in presence of normal fibroblasts [122]. Indeed, CAFs express high levels of epithelial mitogens, as HGF, EGF, b-FGF and cytokines, as SDF-1 and IL-6, which alone are sufficient to induce the transformation of adjacent epithelial cells and thus to favor tumor formation [123]. Modified fibroblasts can directly stimulate the proliferation of cancer cells by providing growth factors, or indirectly by helping these cells to evade apoptosis. They, in fact, secrete survival factors, as insulin growth factor (IGF)-1 and -2 [124, 125], and produce many ECM constituents (mainly various types of collagen), thereby promoting the ligation between integrin receptors and collagen fibers [126]. Both actions promote tumor cells survival via activation of the PI3K/Akt signaling pathway (Figure V).

In addition to providing part of the ability of cancer cells to resist apoptosis, the CAFs-mediated ECM remodeling can also promote tumor invasion and metastasis. Activated fibroblasts, in fact, are able to cause qualitative and quantitative changes in ECM, which becomes stiffer [127, 128]. Part of this process can be attributed to an increased number of covalent cross-links between collagen fibers and other ECM components due to an excess activities of lysyl oxidase (LOX), which is expressed by fibroblasts in the early stage and also in carcinoma cells in the later one [126, 129]. Increase in mechanical force as a result of LOX activity facilitates metastatic
process [126] (Figure V). Moreover, ECM anomalies, including rigidity, contribute, together with an altered vasculature, to increase interstitial fluid pressure supporting tumor drug resistance [130] (Figure V).

CAFs are also a source of ECM-degrading enzymes, as MMPs and plasminogen activator (Figure V). In particular, stromal cells from colon and breast carcinoma express the urokinase-type plasminogen activator (uPA) system, composed of uPA and uPA receptor (uPAR), which induces the turnover of ECM through the activation of plasminogen to the serine protease plasmin [131]. These proteases, through the degradation of ECM, create a physical path enabling tumor cells to penetrate basement membranes, by facilitating the invasion of surrounding tissue. Other functions of MMPs and plasmin include the ability to cleave and thus to activate latent growth factors, pro-inflammatory cytokines and their receptors, to release ECM-bound growth factors, or to cleave cell adhesion molecules, contributing to increase cancer cells proliferation, their motility, EMT and angiogenesis [132, 133]. These actions have been elucidated for MMP-1, MMP-3 (also known as stromelysin 1), MMP-13 and plasmin. The target of MMP-1 is the protease-activated receptor 1 (PAR1), a unique class of G protein-coupled receptors that, cleaved at the proper site, generate Ca$^{2+}$-dependent signals promoting cancer cells migration and invasion [134]. MMP-3 directly cleaves E-cadherin ectodomain at the cell surface, leading normal mammary epithelial cells to lose cell-cell adhesion and to activate EMT program [135]. MMP-13 releases VEGF from ECM promoting tumor angiogenesis and thus the invasive phenotype [136]. Plasmin, instead, can activate some MMPs, such as MMP-3 and MMP-13 [137-139].

In addition, CAFs are able to affect cancer cells motility by secreting soluble mediators, as TGF-β, HGF, VEGF, FGF and SDF-1 [66, 140] (Figure V). Recently, Luga et al. showed a novel mechanism of communication between cancer and stromal cells. These last, in fact, are able to produce small membrane vesicles (in particular exosomes), which play a key role in promoting breast cancer cells protrusive activity and motility via Wnt-planar cell polarity (PCP) signaling [141] (Figure V).

Further, there is evidence that stromal fibroblasts favor the dissemination of malignant cells through lymphatic and blood vessels, as well as are important in preparation of metastatic niche [142-144]. In keeping with this idea, cancer cells, endowed of self-renewal and tumor propagating capacity, function as “seeds”, instead the distant tissue together with fibroblasts derived from the primary tumor, represents the “soil” [145, 146]. In fact, CAFs co-traveling with metastatic tumor cells reach the secondary site, where participate in the formation of a
Introduction

microenvironment permissive for the growth of metastatic colonies [147]. In this new location cancer cells induce the activation of resident normal fibroblasts [148]. Other important factors secreted by activated fibroblasts in tumor microenvironment are pro-inflammatory cytokines, as interleukins, interferon and member of the tumor necrosis factors (TNF) family [149] (Figure V). In particular, expression of chemo-attractant cytokines and chemokines by intratumoral fibroblasts plays a key role in the recruitment of immune cells that, in turns, promote angiogenesis and metastasis [150]. Recent study showed that fibroblasts express a pro-inflammatory gene signature, which is already activated at initial hyperplastic stage in multistep skin tumorigenesis [151]. Therefore, fibroblasts are “educated” by cancer cells to express genes encoding several cytokines, including SDF-1, CXCL14 and CCL7 (Figure V). The secretion of SDF-1 from CAFs enhances the mobilization of endothelial precursor cells from bone marrow and their recruitment into the tumor neovasculature [152]. Furthermore, SDF-1 increases the invasive capacity of pancreatic cancer cells and, together with CXCL8 produced by these malignant cells, promotes the complete angiogenic responses (i.e. proliferation, invasiveness and tube formation) of recruited endothelial cells [153]. CXCL14 expression in prostate cancer CAFs is up-regulated, too. This factor acts in autocrine fashion increasing both proliferation and migration rate of activated fibroblasts, which, in turns, promote tumor growth, angiogenesis and macrophage infiltration [154]. In a similar way, CCL7, up-regulated in fibroblasts associated to oral squamous cell carcinoma (SSC) by paracrine IL-1α secretion from these malignant cells, increases the invasiveness of oral SSC [155].

Another way used by altered fibroblasts to support tumor progression is by engaging a metabolic interplay with cancer cells. Stromal fibroblasts, in fact, are able to participate in the complex regulation of tumor metabolism, but there are opposite hypotheses about how this is done. In 2006, Koukourakis et al. proposed that cells within tumor microenvironment establish a harmonious metabolic collaboration, where CAFs express metabolic pathways complementary respect to cancer cells [156]. According to Warburg effect, tumor cells use glucose by aerobic glycolysis producing lactate [157-159], and to compensate the lower efficiency of adenosine triphosphate (ATP) production, due to incomplete glucose oxidation, increase the uptake of this sugar [160-162]. This behavior allows the diversion of glycolytic intermediates into various biosynthetic pathways in order to form macromolecules and organelles, and thus new cells [163, 164]. In this context, stromal cells buffer and recycle products of anaerobic metabolism of cancer cells sustaining their survival [156].
In 2009, instead, Pavlides et al. proposed a different model, whereby tumor cells induce a metabolic shift toward an aerobic glycolysis in stromal fibroblasts. The energy metabolites produced from aerobic glycolysis, *i.e.* lactate and pyruvate, are used by cancer cells in the mitochondrial tricarboxylic acids (TCA) cycle for ATP production via oxidative phosphorylation. This new theory is also known as “reverse Warburg effect” [165].

However, to better understand the metabolic interplay between tumor and stromal cells will be needed further confirmations.

**Figure V. Interactions between cancer cells and fibroblasts within tumor microenvironment.**
Cancer cells produce growth factors, cytokines and other molecules, which induce and maintain the fibroblasts activated phenotype. Once activated, fibroblasts produce growth factors and cytokines that sustain tumor progression by promoting ECM remodelling, cell proliferation, angiogenesis and EMT. IL, interleukin; INF, interferon.

**Endothelial Cells**
Other determinant cellular elements of stromal compartments are tumor-associated endothelial cells (ECs). ECs have a flattened shape and form a sheet (the endothelium) lining all blood vessels, which acts as cellular interface between the circulating blood and the vessel wall. ECs have an important role in tumor angiogenesis, in fact, angiogenic growth factors secreted by tumor cells or cells of the reactive stroma can directly activate receptors present on ECs promoting endothelial sprouting, branching, differentiation and survival [166, 167]. The formation of new blood network can occur by two mechanisms: vasculogenesis and angiogenesis. In the vasculogenesis, endothelial progenitor cells, present in the
vessel wall or recruited from the bone marrow, contribute to the formation of tumor vessels [168, 169].

Angiogenesis, instead, comprises two different mechanisms: endothelial sprouting and intussusceptive microvascular growth (IMG). The sprouting process is based on endothelial cells migration, proliferation and the budding of new tubes or the formation of bridges between existing ones. IMG is a phenomenon of splitting angiogenesis, where the existing vessels lumen is divides by the formation and insertion of tissue folds and columns of interstitial tissue [170, 171]. Besides the participation in tumor neovascuature, ECs serve as interface between circulating blood cells, tumor cells and the ECM, thereby playing a central role in controlling leukocyte recruitment, tumor cells behavior and metastasis formation [172].

**Pericytes**

Pericytes are contractile cells, related to vascular smooth muscle cells, which wrap around the endothelial cells, establishing with them a close physical contact in the outer surfaces of the finest branches of the vascular tree (the capillaries and sinusoids). Recent studies showed that pericytes are associated with the neovasculature of most, if not all, cancers. In this context, they can stabilize blood vessels, inhibit endothelial proliferation, maintain capillary diameter, regulate blood flow and provide endothelial survival signals via heterotypic contacts and soluble factors [173-175]. Their recruitment into tumor blood vessels is dependent on PDGF-B secreted by endothelial cells [176]. Other studies, instead, found that tumors with few pericytes density on their vasculature were associated with an increase in the number of metastases [173, 177]. For these reasons, the role of pericytes in tumors is not completely understood and future research is needed.

**Immune/inflammatory cells**

Tumor infiltrating cells of immune/inflammatory system include populations with a different phenotype and thus functionally heterogeneous, mainly macrophages, dendritic cells (DCs), myeloid-derived suppressor cells (MDSCs) and neutrophils (*Figure II*). These cellular effectors can act in opposite ways both antagonizing or promoting tumor development, therefore the frequency of infiltrating inflammatory cells, their specific subset, as well as their maturation stage and spatial location within tumor microenvironment have determinant effects on clinical and immunologic outcomes [178, 179].

Macrophages are abundant components of tumor microenvironment, they originate from CD34+ bone marrow progenitors, which, in the circulation system, differentiate into monocytes and, once recruited in peripheral tissue, mature into macrophages
and exert specific immunological functions [180]. In tissues, monocytes can differentiate in two different phenotypes classified as M1 and M2 responses [181, 182]. Their M1 polarization is mediated by inflammatory mediators, such as granulocyte macrophage-colony stimulating factor (GM-CSF), interferon-γ (IFN-γ) and lipopolysaccharide (LPS) [183]. Type 1 activated macrophages secrete pro-inflammatory cytokines and chemokines, including CXCL19 and CXCL10 leading helper T lymphocytes 1 (Th1), Th17 and natural killer (NK) cells development and differentiation [184].

M2 profile, instead, is induced in response to macrophage-colony stimulating factor (M-CSF), IL-4, IL-10, IL-13, IL-21, CC chemokine receptor 4 (CCR4), or to immunosuppressive agents as Activin A, corticosteroids, prostaglandins (PGs) and vitamin D3 [181, 185]. M2 macrophages express a different set of cytokines and chemokines, such as CCL17, CCL22 and CCL24 promoting regulatory T cells recruitment and development [172]. According to their phenotypic characteristic, M1 macrophages have high microbicidal activity, immunostimulatory function and are present in incipient tumors, where are capable to kill tumor cells; on the contrary, M2 macrophages encourage tissue repair and remodeling, neoangiogenesis process and tumor invasion and metastasis [184]. Tumor cells can regulate the function of tumor-associated macrophages (TAMs), “educating” them toward an M2 phenotype [186-188] (Figure II).

Dendritic cells, another type of bone marrow-derived mononuclear cells, are the preeminent antigen-presenting cells (APCs) for T lymphocytes in lymphoid organs and in tissue. In human, two distinct subpopulations of DCs have been identified, myeloid DCs (MDCs) and plasmacytoid DCs (PDCs) [189, 190]. Although their role is not yet clear, both types of DCs are implicated in tumor development but with different functions. MDCs inhibit tumor neoangiogenesis by producing IL-12 [191], on the contrary, PDCs, attracted in tumor microenvironment and protected by CXCL12 secreted by tumor cells, induce not only the formation of new vessels by producing TNF-α and IL-8 [192, 193] but also tumor progression and metastasis by secreting proteases, like MMP-1, -2, -3, -9 and -19 and their inhibitors, as tissue inhibitor metalloproteinases (TIMP) -1 and -2 [194].

In addition to these “mature” infiltrating cells, also MDSCs, an immature population of myeloid cells precursors of DCs, macrophages and/or granulocytes, are present in tumors [195, 196]. In this context, they are induced by various factors produced by malignant cells and/or cells of tumor microenvironment [197, 198] and act as tumor-promoting cells by inhibiting innate and adaptive immunity, and by hindering immunotherapy [199].
Also neutrophils are a component of the immune microenvironment of solid tumors [200-203]. These cells are recruited by CXCL8, a chemoattractant expressed by both cancer and stromal cells of many types of human tumors [201, 204]. Neutrophils are able to promote angiogenesis process by directly secreting VEGF, or inducing its release, or that of b-FGF from ECM, by producing MMPs [205, 206], but like other inflammatory cells also possess antitumor activity. In fact, they can kill tumor cells by releasing proteases, membrane perforating molecules, reactive oxygen species (ROS) and cytokines, in particular TNF-α and IL-1β [207]; otherwise, according the signals within tumor microenvironment, can inhibit angiogenesis by producing elastase [208, 209].

**Hypoxia in the tumor microenvironment**

O₂ is one of the most important elements required to sustain aerobic life. In aerobic organisms, as humans, cellular respiration encompasses a set of redox metabolic reactions based on the oxidation of glucose to carbon dioxide (CO₂) and the reduction of O₂ to water in order to generate the energy (ATP) necessary for biological processes.

The air we breath contains about 21% O₂ at atmospheric pressure of 760 mmHg, i.e. a value of 159 mmHg, but, already in the pulmonary alveoli, O₂ pressure (pO₂) comes down to about 2/3 to the one present in the ambient (66% of 159 ~ 100 mmHg, that corresponds to a concentration of 14%). When the arterial blood reaches tissues peripheral capillaries, pO₂ is still 100 mmHg, whereas that of interstitial fluids is 30 mmHg. This generates a pressure gradient which favors the movement of O₂ from the blood into the adjacent tissue and thus its diffusion into the cellular mitochondria [210].

The intracellular pO₂ necessary to satisfy normal metabolic requirements is 1-3 mmHg. On the contrary, it is known, that in the context of cancer mass, among areas with normal O₂ concentration, are present microregions with very low (down to zero) O₂ partial pressures. In the tumor microenvironment, the impairment of O₂ delivery is related to the decrease of perfusion and diffusion. The first is associated to an inadequate blood flow caused by structural and functional abnormalities of tumor neovascularization. The latter is due to an increase of distance between vessels and cells present within cancer mass as a result of tumor expansion and often leads to cell death by necrosis [211, 212]. Studies concerning the oxygenated status of the tumor showed that: the median pO₂ is lower in cancers compared to their normal counterparts; tumor microregions with low pO₂ cannot be predicted by clinical size, stages, grade, histology and site; the oxygenation status of different
tumors is generally more variable than that of different areas of the same tumor; the oxygenation status of recurrent cancers is lower than that of the corresponding primary ones [213].

In solid tumors, the critical O\textsubscript{2} partial pressure required to maintain the biological functions is between 45-50 mmHg in end-capillary blood and 0.02 mmHg in cytochromes. In fact, in the one hand, tumor cells reduced O\textsubscript{2} consumption (i.e. respiration rates) when the pO\textsubscript{2} in the blood at the venus end of the capillaries drops below 45-50 mmHg [214, 215] (Figure VI). On the other hand, cytochromes aa\textsubscript{3} and c require O\textsubscript{2} partial pressures greater than 0.02-0.07 mmHg to maintain respiration [216-218] (Figure VI).

![Figure VI](image)

**Figure VI.** Critical oxygen partial pressures that characterize the upper limit of the hypoxic range, below which activities or functions of tumor cells progressively change. Open bars: therapy form; hatched bars: cellular functions; solid bars: functions at the subcellular and molecular levels. The bars indicate the respective hypoxic ranges, with the lengths of the bevels showing the variation in threshold values as found by various authors for different end points [253].

The hypoxic microenvironment is able to affects the behavior both of malignant and stromal cells (mainly fibroblasts and macrophages) and thus influences tumor propagation. In particular, hypoxia can induce a significant lengthening of G\textsubscript{1} phase or the arrest into it, differentiation, programmed cell death and necrosis [219-226]. The induction of these phenotypes may explain delayed relapses, quiescent micrometastasis [227, 228] and growth retardation in large tumor masses [229].
Into anoxic areas, instead, cells arrest their progression into cell cycle regardless of the phase in which they are.

Besides to the impairment of neoplastic growth, hypoxia can promote tumor development by enabling the cells to adapt to low pO$_2$ or to move from the original site to more suitable locations. Hypoxia induces the transcription of glycolytic enzymes (including hexokinase 2 and lactate dehydrogenase), glucose transporters (GLUT1 and GLUT3) (Figure VII), angiogenic molecules, survival and growth factors (such as VEGF, PDGF-β, angiogenin, Cyr61, TGF-β, IGF-2 and IL-8), enzymes, proteins able to promote tumor invasiveness (as uPA), chaperones and other resistance-related proteins [230-244], as well as the inhibition of integrin gene expression, thus supporting cell detachment [245]. The hypoxia-induced phenotype is the result of many variables, including the degree of hypoxia and microenvironmental epigenetic factors. For example, hypoxia-inducible factor 1 (HIF-1), the master transcription factor induced in these stress conditions and the main responsible for the transcription of many genes encoding the proteins listed above, is able to exert opposite functions. Depending on the severity of hypoxia, HIF-1 can be in the dephosphorylated or phosphorylated status. The first form exerts pro-apoptotic effects, the other does not [246]. In addition, hypoxia can promote genomic instability (through point mutations and chromosomal aberrations) by increasing the number of genetic variants, and exerting a selective pressure can favor the expansion of the clone most suitable for this microenvironmental stress [232, 247-252] (Figure VI). Despite these observation is not yet clear the level of O$_2$ at which hypoxia starts and causes biological problems.

**Acidosis in the tumor microenvironment**

The main effect due to tumor hypoxia is the decrease of mitochondrial functions (i.e. an impaired oxidative phosphorylation) and the shift to the glycolytic metabolism, which is a less energy-efficient process, but that does not rely on the presence of O$_2$ [254, 255]. This “glycolytic switch” is often permanent and persist after reoxygenation because the metabolic intermediates (lactate and pyruvate) can be used for anabolic reactions leading to the biosynthesis of amino acids, nucleotides and lipids, thus providing a selective advantage to highly proliferative tumor cells [254, 255]. In addition, Sonveaux *et al.* showed that the lactate produced by tumor cells within hypoxic areas is used by malignant cells located in the vicinity of blood vessels as substrate for oxidative phosphorylation. As result of this symbiotic relationship, the limited glucose available in the tumor mass is used in an effective way [256]. In fact, the switch to glycolysis requires an increased
consumption of glucose and leads to an excessive generation of acidic catabolites, such as CO$_2$, lactic acid, carbonic acid and protons (H$^+$) (Figure VII). The release of these waste products in the extracellular space, together with the abnormal structure and function of tumor vasculature, is cause of the decline of extracellular pH (pHe), which usual is in the range of 6.5-7.0 [254, 257-260] (Figure VII).

**Figure VII. Proteins involved in pH regulation in cancer cells.** The pH-regulating system that participates in cytoplasmic alkalinization of tumor cells includes NHE1, the plasma membrane V-ATPase and MCTs, whose function is to actively export acid, and AE, NBCs, which, instead, import HCO$_3^-$. Also carbonic anhydrases (CA II, CA IX and CA XII) contribute to cellular alkalinization by catalyzing the reversible hydration of CO$_2$ to H$^+$ and HCO$_3^-$. Hence, the pH is slightly alkaline (pH 7.2-7.4), whereas the pHe is slightly acidic (pH 6.5-7.0). The glucose transporter GLUT1 (which is up-regulated in most tumors) imports glucose into cancer cells. The expression of the genes encoding most of these proteins is under the transcriptional control of HIF-1. CBP, cyclic AMP-responsive element-binding (CREB) protein; p300, histone acetyltransferase p300 [255].

Besides hypoxia, also the acidity of the extracellular milieu is a stress condition, since lowering of the pHe makes more difficult the control of the intracellular one. In fact minimal variations in intracellular pH (pHi), as low as 0.1 pH units, may affect several biochemical and/or biological processes, as energy production, enzyme function, membrane integrity, metabolism, proliferation, migration, invasion and metastasis, drug resistance and apoptosis [255, 257, 261-264]. pH homeostasis in any cell type is a critical process that involves complex molecular mechanisms (i.e. a variety of proteins and buffer systems) [265], but this get tangled
up for tumor cells, that prefer a more alkaline pH (pH 7.4 or more) compared to their normal counterpart [256, 261, 265-268] (Figure VII).

In cancer cells, the main players responsible for maintaining the alkaline pH and the acidic pHe are: carbonic anhydrase (CA) II, CA IX and CA XII [269-271]; vacuolar proton pump ATPase (V-ATPase) [272]; the anion exchangers AE1 (also known as SLC4A1), AE2 (also known as SLC4A2) and AE3 (also known as SLC4A3) [273, 274]; Na+/HCO₃⁻ cotransporters (NBCs) [275]; electroneutral Na⁺-driven Cl⁻/HCO₃⁻ exchanger (NDCBE; also known as SLC4A8) [275]; Na⁺/H⁺ exchanger 1 (NHE1; also known as SLC9A1) [275]; the monocarboxylate transporters MCT1, MCT2, MCT3 and MCT4 [276, 277] (Figure VII). The expression of these proteins enables cells to develop defense mechanisms providing a selective advantage, and thus fostering the survival even in an extracellular microenvironment with an increased acid load [278].

**Carbonic Anhydrases**

The carbonic anhydrases (EC 4.2.1.1) are metalloenzymes whose major function is the catalysis of the reversible hydration of carbon dioxide to bicarbonate and protons (CO₂ + H₂O ↔ HCO₃⁻ + H⁺), a reaction of critical importance in most organisms since the bicarbonate/carbonic acid system is the main buffer in all living cells. They are present in Archaea, prokaryotes and eukaryotes and are encoded by members of three independent gene families: α-CAs (present in vertebrates, eubacteria, algae and cytoplasm of green plants), β-CAs (mainly in eubacteria, algae and chloroplasts of both mono- as well as dicotyledons) and γ-CAs (found in Archaea and some eubacteria) [279-281].

CAs perform their enzymatic function mainly in presence of zinc, but a cadmium-containing form was found to be expressed in marine diatoms during zinc limitation [282]. In mammals, 16 CA isoforms have been described (in human only 15 because CA XV is not present in primates). They differ in subcellular localization, tissue distribution, level of activity and susceptibility to different classes of inhibitors. There are cytosolic isoforms (CA I, CA II, CA III, CA VII and CA XIII), membrane bound ones (CA IV, CA IX, CA XII, CA XIV and CA XV), mitochondrial (CA VA and CA VB) and secreted isoymes (CA VI). In addition, there are three catalytic isoforms (CA VIII, CA X and CA XI), which are also known as CA-related proteins (CARP) [283, 284]. Among them all, CA IX and CA XII are overexpressed in many solid tumors, where they have an important role during the phase of progression, in metastases formation and in drug resistance [269-271, 285, 286].
CA IX
In 1992, Pastorekova and coworkers identified a cell density-regulated plasma membrane antigen in human HeLa cell line derived from cervical carcinoma using the monoclonal antibody M75 [287, 288]. Subsequently, cDNA sequence analysis of this antigen, named “MN protein”, showed a 257 amino acid residues long polypeptide highly homologous to the mammalian CA catalytic domain [271, 289]. Thus, being the ninth CA identified, the “MN protein”, was renamed CA IX [271, 289].

CA IX protein is composed from a N-terminal extracellular domain linked through a hydrophobic transmembrane region with a C-terminal intracellular tail. The extracellular part, which represents the 90% of the whole protein is formed by a signal peptide (SP), a proteoglycan domain (PG) similar to the keratan sulfate-binding domain of a large proteoglycan aggrecan, and by the CA catalytic domain [271, 289] (Figure VIII).

![Figure VIII. Domains organization of the CA IX protein. SP: signal peptide, PG: proteoglycan-like domain, CA: catalytic domain, TM: transmembrane segment, IC: intracellular, cytosolic tail [292].]

Unlike other CA, isoform IX has a dimeric nature resulting from an intermolecular disulfide bond between two adjacent monomers and stabilized through two hydrogen bonds and numerous van der Waals interactions [290, 291]. Each monomer contains a compact globular catalytic domain, where the active site is located in a large conical cavity, that from the surface of the protein goes down to its center [269, 291]. In the bottom of this cavity is located the zinc (II) ion. Alongside of the active site is positioned the PG-like region, whose role is to ensure a better catalytic efficiency at more acidic pH values [292, 293]. In fact, pKa value measured for CA IX catalytic domain alone is 7.01, on the contrary, whenever the protein construct contains also the PG region the optimal catalytic activity is at pH 6.49 [291]. PG domain function is probably mediated by its negatively charged amino acids. This region, by interacting with positively charged residues close to the active site, can both act as a cap controlling substrate accession and participate in the proton-transfer reaction [291].
Also the cytoplasmic tail can modulate CA IX catalytic activity both through the transmission of inside-out signaling to extracellular enzyme domain [294, 295] and increasing its activation [296, 297]. Similar to some cytosolic (CA I and CA II) and all extracellular CA isoforms, CA IX belongs to the highly active human α-CAs, as well as is susceptible to inhibition by anions and sulfonamides/sulfamates [269, 290, 298, 299].

In normal tissue, CA IX is mainly expressed on the basolateral surface of proliferating crypt enterocytes of the duodenum, jejunum and ileal mucosa [300], while a weak expression is present in the epithelia of male efferent ducts [301]. On the contrary, its expression is strongly increased in many type of tumor, including gliomas/ependymomas, mesotheliomas, papillary/follicular carcinomas, as well as carcinomas of the bladder, uterine cervix, kidneys, esophagus, lungs, head and neck, breast, brain and many other [302].

CA IX expressed in malignant cells has no mutations and its cDNA sequence is identical to that of normal cells. Hence, the association of this enzyme with tumors is exclusively related to its expression [303]. In tumor context, the increase of CA IX expression can occur in different conditions. In response to hypoxia, in increased cell density circumstances [304] and, for specific cell types, in acid microenvironment and during glucose deprivation [305-307], HIF-1 binds hypoxia responsive elements (HRE), which are localized in CA9 gene promoter just in front of the transcription start site at position -3/-10, and induces transcription of CA9 gene [304] (Figure VII). In addition, functional inactivation of VHL (von Hippel Lindau) tumor suppressor gene, a member of E3 ubiquitin-ligase complex involved in the degradation of \( \text{O}_2 \)-sensitive α-subunit of HIF-1, results in the hypoxia-independent expression of HIF-1 and thus of CA IX [308].

In solid tumors, CA IX overexpression is associated with poor prognosis [309-312].

**CA IX functions in tumor cells**

The prominent function of CA IX in the context of tumor microenvironment is the enzymatic catalysis. Isoform IX is one of the membrane bound CA isozymes whose catalytic domain is localized at the extracellular surface of the plasma membrane. This location of active site supports its role in controlling pH dynamics in solid tumors. CA IX is a peculiar member of CA family, in fact possesses several properties highly suitable for the tumor physiology. On the contrary to the other CA, isoform IX is insensitive to high lactate concentration found in the tumor [313], possesses the PG-like domain which enables it to function most efficiently at more acidic pH values typical of cancer mass [275, 292, 293], participates in the extracellular acidification [286] and regulates the intracellular pH [314].
Extracellular hydration of CO₂, indeed, results in the production of protons and bicarbonate. The first remains outside of the cells and increase the acidity of extracellular space, thus promoting tumorigenic transformation, chromosomal rearrangements, ECM breakdown, migration and invasion, protease activation and growth factor production [257, 315, 316]. In addition, acidic pHe can impair immune functions and influence the effect of conventional therapy on tumor cells, modulating the uptake of cancer drug [317].

The other product is transported inside the cells, where contributes to the production and the maintenance of alkaline pHi supporting cell survival and proliferation [317]. Vince and Reithmeier proposed that this transport could be mediated by a spatial and functional cooperation between bicarbonate transporter(s) and CA IX [318]. Subsequently, McMurtrie et al. showed that this cooperative complex (called “metabolon”) is present in various cellular/tissue contexts and that can include different combinations of transporters and CA isozymes (AE1-3, NBC and CA II, CA IV and CA IX) [319]. It is also to note that CA IX is able to regulate pHi homeostasis both in presence and absence of the key pHi regulating protein NHE1 [320].

Besides the control of CO₂ metabolism, CA IX can directly participates to cell adhesion and migration both mediating the attachment of cells to solid support and competing with E-cadherin for the interaction with β-catenin, thus weakening cell-cell contact [321, 322]. Recent studies showed that also the PG-like N-terminal extension of CA IX extracellular domain can mediate cell adhesion [323]. This region, in fact, contains a sequence similar to that of aggregan attachment domain and thus may be capable of binding ECM components [289, 323]. Moreover, tumor cells silenced for CA IX are less able to form cancer mass in vivo. Tumor growth is further reduced when the knock-down of CA IX is combined with that of CA XII, suggesting a functional complementarity between the two isoforms [320].

CA XII and CA II

Besides CA IX, other CA family members related to tumor biology are the isoforms XII and II. CA XII is a membrane-bound isozyme whose catalytic site is exposed at the cell surface; instead, CA II is a cytosolic isoform [283, 284]. CA XII is overexpressed in renal cancer cells [285, 324], breast cancer [325], and other many tumors [326]. This isozyme participates in the regulation of pHi and pHe and shows a complementary function compared to CA IX [320]. In fact, the knock-down of isoform IX results in up-regulation of XII one (at both mRNA and protein level) [257]. In breast cancer, CA XII has been shown to be a marker for good prognosis.
on the contrary, its spliced shorter variant seems to be a marker of poor prognosis in astrocytomas [328]. Unlike isoforms IX and XII, CA II is only weakly expressed in many tumors. Nevertheless, it is possible that, thanks to its high catalytic activity, is still able to participate in the maintenance of alkaline pH and acidic pHe contributing to tumor growth and survival [257, 329]. Alternatively, it could perform its function at the level of tumor vasculature, where its expression is significantly higher than that of normal endothelium [330]. In the stomach, Pan et al. showed that knockout of CA IX leads to increase in CA II, and vice versa [331]. Although the reason why a membrane-bound isoform is compensated with a cytosolic one is intriguing, it is possible that both are able to interact with another protein by determining the formation of pH-regulating complex [257]. In order to clarify the function of both CA XII and CA II in the context of tumor microenvironment, further studies are required.

**Membrane transporters**

Other factors that contribute to pH homeostasis in tumor cells are the isoform 1 of NHE [332, 333], MCTs and bicarbonate transporters (BTs), including NBCs, AE2s and NDCBEs [334, 335]. NHE1 couples the export of H+ across biological membranes to the import of Na+, MCTs couple H+ export with that of monocarboxylates (lactate and pyruvate), NBCs translocate Na+ and HCO$_3^-$ together in the same direction, AE2s are responsible for Cl$^-$/HCO$_3^-$ exchange, and NDCBEs act as Na+-dependent Cl$^-$/HCO$_3^-$ exchangers but are expressed by a limited number of cell types. NHE1, NBCs, NDCBEs perform their function using the energy stored in the inwardly directed electrochemical Na$^+$ gradient generated by Na$^+$-K$^+$ ATPase, the inward Cl$^-$ gradient, instead, provides the driving force for AE2 activity [336]. BTs [337], MCTs [338], but especially NHE1 [333, 339-341] are important proteins for cytoplasmic alkalization and have a role in cell migration and invasion.

During migration and invasion processes, cancer cells change their morphology by acquiring the front-rear polarity and forming lamellipodia and invadopodia, respectively [342] (Figure IX). The polarization of tumor cells along their longitudinal axis is fostered by NHE1, which is linked to actin filaments and controls the organization of the cytoskeleton [339, 343-345], as well as contributes to cytosolic alkalization and extracellular acidification [346-349]. In fact, during cell migration NHE1 [343, 346, 347], together with NBC1 and AE2 [351-353], accumulates at the leading edge (Figure IX). In this location, they mediate ions entry that, together with water influx across aquaporins (AQP1) [354], supports the outgrowth of the
lamellipodium [351-353]. In addition, they form the pH-regulating machinery which generates a pH-i gradient from the front toward the rear part of cells. The neutral-alkaline pH-i at the leading edge promotes cofilin activity which, by severing actin filament (F-actin), generate free barbed ends providing sites for further actin polymerization and thus driving membrane protrusion [355, 356] (Figure IX).

Recent studies showed that the “metabolon” previously described [318, 319] is formed also at the lamellipodia present in the front of the cells, where NBCs and AE1, -2, -3 establish a functional cooperation with CA IX, whose role is to produce bicarbonate and to maximize the rate of its transport across the plasma membrane contributing to increase pH-i [357-359].

At the rear end, instead, gelsolin, activated by acidic pH-i and high Ca$^{2+}$ concentration, controls the length of actin filaments by its severing and capping activities [360-362]. Gelsolin, in fact, helps to recycle actin promoting the retraction of the rear end of a migrating cell [363].

**Figure IX. Role of protons in cell motility.** pH homeostasis is crucial for tumor cells migration and invasion. BTs (including NHE1, NBC1, AE2), MCT4, AQPs and CA IX, accumulate at leading edge membranes and promote the cytoplasmic alkalinization and pH-e acidification. pH-i alkalinization activates cofilin, an actin-binding protein capable of increasing the recycling of actin monomers (globular actin, or G-actin) at the rear of “older” actin filaments (filamentous actin, or F-actin), thereby inducing de novo localized actin assembly, cytoskeleton reorganization and membrane protrusion. pH-e acidification results in the modulation of integrin-mediated cell-matrix adhesion, thus facilitating cell migration. At the trailing edge, instead, alkaline pH-i and acid pH-e drive the retraction of the rear part of migrating cells [modified from ref. 336].

Oppositely to the pH-i gradient, the pericellular proton concentration within the glycocalyx, generated by the pH-regulating complex described above, is up to twice as high at the leading edge than at the rear part of migrating cells [347-349] (Figure IX). This pH-e gradient coordinates the formation and release of focal adhesion contacts mediated by integrins with ECM or between cells.
Integrin-mediated interactions, indeed, are sensitive to proton concentration [347, 349, 364-366]. At the leading edge, the extracellular acidification mediated by NHE1 facilitates the formation of focal adhesion contacts, stabilizes the existent ones [348, 349] and fosters the exocytosis and function of MMPs by inducing both them protonation or that of their substrates, thus promoting proteases activity [367, 368]. The alkaline pH of the rear edge, instead, weakens the adhesion to ECM or to neighbored cells [363] and increases the entry of Ca$^{2+}$ into cells through the proton-sensitive TRPM7 channel promoting gelsolin activity [369]. Like NHE1, NBC1 and AE2, also MCT4 accumulates at the leading edge, where export H$^+$ and monocarboxylates, contributing to lowering the pHe [370] (Figure IX).

Besides H$^+$, the exported lactate may promote cell migration. It, in fact, up-regulates the synthesis of ECM components (such as hyaluronan and type I collagen) to which cells can adhere via a proton-sensitive mechanism, and thus migrate [371, 372]. Lastly, it is important to note that as NHE1 is one of the most prominent proteins regulating pH$i$, it has also an important role in supporting cancer cells survival and proliferation. It has been demonstrated that both its pharmacological inhibition [373-375] and its lacking activity [376, 377] in cancer cells results in a drastic reduction of tumor growth in vivo.

**The intercellular communication**

In pluricellular organisms, intercellular communication is instrumental for the survival and the function of cells and to ensure the integrity of tissues. Typically, the exchange of informations occurs through the transmission of electrical or chemical signals. The first allows the diffusion of nerve impulse across electrical synapses, formed of gap junctions or nexus, which enable the free flow of ions from one cell to another. The latter is mediated by extracellular molecules, such as nucleotides, lipids, short peptides or proteins released by cells. These molecules bind to specific receptors on other cells and activate intracellular pathways, thus modifying their physiological state. Alternatively, cells can communicate with each other after direct cell-cell contact through mechanisms of nibbling, trogocytosis and nanotubes. The mechanism of nibbling concerns the unique ability of DCs to capture antigen from live cells by physically stripping large membrane fragments without inducing death of the donor cells [378]. The trogocytosis, instead, describes the transfer of plasma membrane fragments from one cell to another, triggered by receptor signaling following cell-cell contact without cell death induction [378]. It is an active and, in some circumstances, bidirectional process that, compared to other transfer mechanisms, occurs very quickly (within minutes after cell-cell...
This phenomenon was mainly observed in cells of the immune systems, including B cells, T cells, NK cells, monocytes [381] and DCs [382]. It was documented that both MHC (major histocompatibility complex) class I and class II proteins can transfer from APCs to T cells [383-388], and that many other cell-surface molecules can be transferred, not only to T cells, but also to B and NK cells enabling the coordination of the immune response [389].

Another mode of cell contact dependent protein trafficking is mediated by the formation of membranous channels of 50-200 nm in diameter, called nanotubes, that connect cells over long distances [378]. These nanotubular connections, first described in cultured rat pheochromocytoma PC12 cells [390], are formed by many different cell types, such as T, B, NK cells, macrophages [385, 391-393], and between different cancer cells (breast and ovarian cancer cell lines) and stromal cells (mesenchymal stem cells and ECs) [394]. These structures allow intercellular transfer of organelles (such as mitochondria) [394], of various plasma membrane components, of cytoplasmic molecules [395], as well as of calcium ions, MHC class I, pathogens, small organelles of the endosomal/lysosomal system and ATP-Binding Cassette transporter [396-401].

The intercellular communication mediated by the exchange of proteins can occurs also by trans-endocytosis, a biological process documented, for instances, in Notch-mediated signal between adjacent cells [402-404]. Notch is a transmembrane receptor involved in embryonic development and cell differentiation, and is formed by separable extracellular and intracellular domains linked together by non-covalent bonds [405, 406]. During the process of trans-endocytosis, the part of the receptor present on the outer surface of a cells is cleaved off and undergoes endocytosis into its neighboring cell, where is transferred into endosomes. Simultaneously, the intracellular domain is released in the cytoplasm, translocates to the nucleus, and activates gene transcription [405, 406].

In addition to these mechanisms, another form of intercellular communication involves the secretion by cells of small extracellular membrane vesicles (EMVs) characterized of an approximately spherical structure limited by a proteolipid bilayer and containing bioactive components, such as numerous proteins, lipids and nucleic acids [407-411] as well as, in the case of larger vesicles, mitochondria [412]. These vesicles were observed first in 1978 by Friend et al. in cultures of spleen nodules and lymph nodes from a patient with Hodgkin’s disease [413], and then in 1980 by Poste and Nicolson, who found that vesicles secreted by highly metastatic B16 mouse melanoma cells enable the poorly metastatic ones to metastasize to the lung [414].
Subsequently, these vesicles were detected in the culture supernatant of different cell types both of hematopoietic origin (such as B cells [415], DCs [416, 417], mast cells [418], T cells [419] and platelets [421, 422]) and of non hematopoietic origin (as intestinal epithelial cells [423], tumor cells [424, 425], Schwann cells [426], neuronal cells [427, 428], astrocytes [429], ECs [430] and fibroblasts [431]). In addition, EMVs were found in vivo in diverse body fluids [431], including semen [432-434], blood [435], urine [436, 437], saliva [438], breast milk [439], amniotic fluid [440], ascites fluid [441-443], cerebrospinal fluid [444] and bile [445].

The identification of these numerous forms of intercellular communication supports the concept that “no cell is an island” [446]. All organisms, in fact, are composed by non-autonomous cells capable of interacting with each other thanks to a continuous horizontal exchange of informations.

**Structure and biogenesis of extracellular membrane vesicles**

Eukaryotic cells constitutively release heterogeneous populations of EMVs both in vivo and in vitro, which can be divided into two distinct subtypes, known as exosomes and microvesicles, characterized by different properties, including origin, size, morphology, buoyant density and protein composition.

**Exosomes**

Exosomes are membranous nanovesicles of 30-100 nm in diameter, with a rounded shaped morphology and a floating density of 1.10-1.21 g/mL in sucrose gradient [415, 447]. They arise as intraluminal vesicles (ILVs) in the endosomal compartments called multivesicular bodies (MVBs) by inward budding and pinching at the limiting membrane into the endosomal lumen [448], so they contain cytosolic components and expose the extracellular domains of transmembrane proteins, which thus maintain the same topological orientation as at the endosomal membrane [449, 450] (Figures X-a and X-b). Thereof, MVBs not only represent a late step in the maturation of endosomes to lysosomes (degradative MVBs), but also participate in an alternative process. These compartments, in fact, can fuse with the plasma membrane and release their segregated vesicles into the extracellular space (exocytic MVBs), where upon ILVs are called exosomes [407] (Figure X-a).

Exosomes can originate from multiple cell types, thus their cargo contains both type-specific and common molecules. Examples of cell-type specific proteins are transferrin receptor [451] and integrin α4β1 [452] in exosomes released by reticulocytes; CD3 [451], integrin β2 and the ubiquitin ligase c-CBL [419] in T cell derived exosomes; A33 antigen and the cell-surface peptidase IV/CD26 [423] in exosomes originate by enterocytes. The molecules ubiquitous in exosomes derived
from distinct source, instead, are cytoskeletal proteins (tubulin, actin and actin-binding proteins), molecules involved in the sorting of proteins/cargo, as ESCRT complex (endosomal sorting complex required for transport), chaperones (heat shock protein, as HSP70 and HSP90), proteins involved in signal transduction (protein kinase, 14-3-3 and heterotrimeric G proteins), clathrin, protein involved in transport and fusion (annexins and Rab proteins), several metabolic enzymes (such as peroxidases, pyruvate and lipids kinases and enolase-1), elongation factors and, perhaps, proteins that participate in some common exosomes functions not yet known [453, 454] (Figure X-c).

According to their origin, exosomes do not contain any proteins derived from nucleus, mitochondria, endoplasmic-reticulum or Golgi-apparatus [455]. The process of protein sorting can be mediated by different mechanisms both ESCRT-dependent and -independent. ESCRT machinery is composed of four proteins complexes (known as ESCRT-0, -I, -II, -III) associate with accessory proteins (Alix, VPS4 and tsg101): the ESCRT-0, -I and -II complexes are able to recognize and sequester the mono-ubiquitinated proteins at the limiting membrane of endosomes, instead the ESCRT-III complex acts in the budding and scission phases [456, 457]. On the contrary, the ESCRT-independent mechanisms include: the non-specific engulfment of small portions of cytosol, the transient association of proteins with the transmembrane ones [458] and a process dependents on raft-based microdomains, where ceramide formed from sphingolipids by neutral sphingomyelinase can induce the coalescence of small microdomains into larger ones, promoting domain-induced budding [459]. Alternatively, proteins can be co-sorted in concert with other proteins, such as tetraspanins which are enriched in exosomes where cluster into membrane microdomains [460] (Figure X-b), or flotillin, stomatin and lyn, that are raft-associated proteins [461]. Presence of several sorting mechanisms may induce the formation of heterogeneous subpopulations of ILVs.

The lipid composition of exosomes is similar to that of the plasma membrane of the producing cell [462], nevertheless in comparison to it, exosomes are highly enriched in cholesterol, sphingomyelin and hexosylceramides to the detriment of phosphatidylcholine and phosphatidylethanolamine [463-466]. In agreement with these observations cholesterol-rich MVBs secrete their vesicles cargo, on the contrary, the cholesterol-poor ones act as degradative MVBs [467].

Other components of exosomes are mitochondrial DNA (mtDNA) [468] small non-coding RNAs, as miRNAs (known to control gene expression by regulating mRNA turnover), and mRNAs, which can be translated into proteins by recipient cells, each one can be cell-type specific [410, 469, 470] (Figure X-c). It is noteworthy that
not all mRNAs and miRNAs of a cell end up in exosomes. Their selective incorporation could be mediated by ESCRT-II, which acts also as RNA binding complex [471], by RISC (RNA-induced silencing complex) and its key components GW182 and AGO2 (argonaute), which are enriched in exosomes [472].

After that, ILVs were assembled, the secretory MVBs are transported toward the cell periphery, where fuse with the plasma membrane. Classically, intracellular trafficking and the fusion of compartments require the cytoskeleton (actin and microtubules), associated molecular motors (kinesins and myosins), molecular switches (small GTPase of the Rab family) and the fusion machinery [473].

The same effectors probably participate in the release of exosomes. Examples of Rab proteins involved in the mobilization event are: Rab11, engaged for Ca\(^{2+}\)-induced exosome secretion by the K562 erythroleukemia cell line [474] (Figure X-a); Rab35, required for proteolipid protein (PLP)-enriched exosomes release by oligodendroglial cells [475]; Rab27a and Rab27b, which have a complementary role in spontaneous secretion of MHC class II-bearing exosomes by HeLa-CIITA cells [476], Rab27a, but not Rab27b, also acts in exosome secretion by different mouse mammary carcinoma [477]. In this contest, Rab proteins effect appears to be redundant and cell type dependent, alternatively, these proteins could act upstream of exosomes secretion. In fact, the selective inactivation of each of them only partially affects this process [475, 476].

Subsequently, the fusion of MVBs with the plasma membrane is probably driven by a specific protein machinery, which includes soluble factors (such as N-ethylmaleimide-sensitive factor, NSF, and soluble NSF-attachment protein, SNAP), membrane complexes (such as SNAP-attachment protein receptor) and synaptotagmin family members [478, 479].

Several events can regulate exosomes production, among them, the increase of cytosolic Ca\(^{2+}\) concentration is one of the most trigger [474] (Figure X-a). In addition, DCs were stimulated to release exosomes as the result of the interaction with T cells, that recognize peptide-loaded MHC class II [480]; neuronal cells produce exosomes in response to plasma membrane depolarization; and cross-linking [427, 481] of CD3 in T cells stimulates exosomes release by T cells [419]. The intracellular mechanisms of exosomes biogenesis and secretion are not yet clearly defined and future works are needed. Process understanding, in fact, represents an essential step to further identify exosomes function and significance.
**Introduction**

The generation and composition of exosomes. Membrane proteins are endocytosed via clathrin-coated pits, clustering of proteins in lipid rafts or tetraspanin-enriched membrane microdomains (TEMs). Then, they are addressed to early endosomes (EEs), those gradual maturation toward the late endosomes results in the increase of intraluminal vesicles number. These late endosomes are also known MVBs. The intracellular transport of these vesicles and their cargo selection are facilitated by ubiquitylation, Rab proteins and ESCRT machinery. MVBs can recycle proteins back to the membrane, evolve into lysosomes for degradation, or fuse their membrane with the plasma membrane thus releasing their intraluminal vesicles as exosomes. This last process is promoted by various stimuli, as Ca\(^{2+}\) flux and stress (a, b). The exosomes composition varies with the cell type, but includes some ubiquitous molecules, including Rab proteins, annexins and ARP2-ARP3, which are involved in membrane transport and fusion, adhesion proteins (as integrin and ICAMs), cytoskeleton proteins, tetraspanins and nucleic acids (c). The uptake of exosomes by target cells occurs by different mechanisms: these vesicles can bind to specific receptors (mainly phosphatidylserine receptors), interact unspecifically or fuse with the recipient cells membrane (d). ERM, ezrin-radixin-moesin; GPI, glycosylphosphatidylinositol; ICAM, intercellular adhesion molecule [420].
Microvesicles

Microvesicles (MVs) are membranous particles with irregular shape and constitute a larger and more heterogeneous populations in size compared to exosomes, ranging from 50 to 1,000 nm in diameter [407, 482]. Their buoyant density is not yet been determined, but may overlap that of exosomes [378, 483]. MVs, as well as exosomes, arise through an unconventional mechanism (i.e. not based on the classic signal-peptide secretory transport pathway) [484] but in contrast to the exosomes endocytic origin, they are formed through direct outward budding from the plasma membrane and fission of their connecting membrane stalks [431, 485-487] (Figures XII and XIII).

MVs formation is driven by the acquisition of membrane curvature which requires physical perturbations of the lipid bilayer [488]. These deformations seem to be mainly mediated by proteins and lipids, which can modify membrane shape through different mechanisms. First, cytosolic proteins recruited to the membrane can polymerize with an intrinsic curvature and thus impose it on the membrane [489-492] (Figure XI-a). In this model, the constraints induced by proteins can be supported by lipid aggregation into microdomains, which leads to membrane bending by beginning the budding process [493]. Second, proteins can cause morphological changes in cell membrane according to the bilayer-couple hypothesis. This theory, initially popularized by Sheetz and Singer in 1974, proposes that through the physical insertion of amphipathic moieties into one face of the lipid bilayer, proteins can increase the surface area of this leaflet and thus induce the spontaneous curvature of the bilayer [494-496] (Figure XI-b).

Third, contractile proteins can add or remove tensile forces, stretch only one face of the lipid matrix and thus create a structural asymmetry that would cause bending [497]. Fourth, proteins can contribute to regulate the lipid composition and distribution within the plasma membrane both due to asymmetric lipid synthesis and owing their relocation [498, 499]. Aminophospholipid translocases, in fact, are proteins that regulate the transfer of phospholipids from one leaflet to the other in an ATP-dependent manner. In particular, flippases are translocases that move phospholipids from the outer face to the inner one; on the contrary, floppases perform phospholipid transfer in the reverse direction [500-502]. In this respect, the movement of phosphatidylserine to the outer leaflet promotes membrane budding and vesicles formation [503, 504] (Figure XI-c).
In addition, selective enrichment of cholesterol could decrease local membrane stiffness, alter the relative bilayer surface areas and promote the budding process \([505-507]\) \((\text{Figure XI}-\text{d})\). Hence, MVs shedding occurs at specific locations, where particular proteins and lipids accumulate \([508]\).

Figure XI. Mechanisms of membrane deformation mediated by proteins and lipids. Proteins that assemble with an intrinsic curvature could drive membrane shape \((\text{a})\). Membrane curvature according to the bilayer-couple hypothesis \((\text{b})\). Transfer of lipids to one leaflet \((\text{c})\) and/or selective enrichment of cholesterol \((\text{d})\) result in membrane curvature owing to bilayer surface-area discrepancy between the two leaflets. Black arrowheads indicate the transferred lipids in \((\text{c})\) and cholesterol in \((\text{d})\) \([\text{modified from ref. 488}]\).

Once the bud is formed, it is physically separated from the plasma membrane of donor cells (the process known as fission) thanks to contraction of cytoskeletal structures by actin-myosin interactions \([425, 509, 510]\). In tumor cells, this phase starts with ADP-ribosylation factor 6 (ARF6), a small GTP-binding protein of Ras family expressed in all eukaryotes, which activates phospholipase D (PLD), that, in turn, recruits ERK (extracellular signal regulated kinase) to the plasma membrane. ERK is able to phosphorylate and activate MLCK (myosin light-chain kinase), a kinase that promotes myosin function, cytoskeleton contraction and thus the release of MVs \([425]\) \((\text{Figure XII})\). Vesicles contraction seems to be internally, at the necks of the bud, in this location contractile proteins complete the fission process.
by acting like a drawstring [425, 508]. Besides translocases enzymes activity, also that of contractile proteins requires energetic input [508] (Figure XII).

It is noteworthy that this signaling cascade does not affect exosomes release, supporting the concept that the biogenesis of these subtypes of vesicles involves distinct mechanisms [425].

**Figure XII. The signaling cascade that regulates outward budding and fission of MVs.** ARF6 activates PLD, which recruits ERK to the plasma membrane. ERK, in turn, activates by phosphorylation MLCK, which phosphorylates and activates myosin light chain, thereby triggering the release of MVs [529].

MV production is documented in resting cells, but the rate of this phenomenon becomes significantly higher in response to various stimulations, including increased in cytosolic Ca\(^{2+}\) concentration, cellular stress (such as DNA damage), cytokine exposure, anticancer drug treatment [511-515], and, for DCs, in response to LPS [417, 516] (Figure XIII). Since the release of MVs causes the removal of small portions of membrane from the cell surface, they must be continuously replaced. In resting cells, the maintenance of an appropriate surface area is favor by the constitutive traffic of membrane enriched in vesicles-specific molecules. On the contrary, surface area homeostasis in high rate shedding cells requires a further compensation mechanism. In these activated cells, in fact, vesicles formation seems occur in conjunction with the discharge of non-secretary exocytic vesicles stored in the cytoplasm, which allow to insert “new portions” of membrane in the cell surface [517, 518] (Figure XIII).

Like exosomes, MVs cargo is composed of bioactive components from cytosol, such as nucleic acids (in particular miRNAs) [519, 520], lipids, numerous proteins (including cytokines, oncogenes, growth factor receptors, integrin receptors, proteases and/or MHC class I molecules) [521], whole intact organelles, such as
mitochondria [412] and infectious particles (as HIV, human immunodeficiency virus, and prions) [522-525]. Transmembrane proteins incorporated into MVs conserve the same topological orientation of the parent cell [521]. Since MVs are released by different cell types, their composition depends on the cell from which they originate and the status in which it is [408]. Protein and lipid components of MVs are not random but selectively sorted at the cell surface, among them, there are also the proteins contained and trafficked via the ARF6-regulated endosomal recycling pathway, but compared to the mechanisms involved in exosomes biogenesis, these processes are less defined [526, 527]. However, the understanding about the structure and the biogenesis, not only of MVs but also exosomes, are not yet complete. In fact, despite the different origin, size, morphology, buoyant density and protein composition, MVs and exosomes derived from the cell cultures supernatant are not easy to separate because the size range overlap between the two different vesicles and also small vesicles (100 nm in diameter) may bud from the cell surface [528]. Finally, there is no general consensus as to the best method to isolate the two subpopulations.

![Figure XIII. Generation of MVs. MVs (red membrane) directly shed from the plasma membrane of cells in the resting state or, with a higher rate, from cells activated in response to various stimuli (such as the increase of cytosolic Ca$^{2+}$ concentration and cellular stress, represent as a thunderbolt in the extracellular space). The cargo of microvesicles (gray) is sorted out from the cytosol. MVs release, i.e. the removal of membrane fragment at the cell surface, is compensated by a concomitant input of membrane delivered through the non-secretory exocytic vesicles stored in the cytoplasm (blue membrane) [407].](image)

**Functions of extracellular membrane vesicles**

Initially it was thought that vesicles observed in the cell culture supernatant were cell debris formed during the processes of apoptosis or necrosis in response to damage, or merely membrane fragments artificially released upon *in vitro* cell
handling [530]. Nowadays, the identification of some molecular mediators of biogenesis processes, as well as of certain conditions capable of increasing the production of vesicles, in addition to the findings that EMVs do not contain a random array, but a specific set of proteins both in the membrane and in their inside, allowed to assert that EMVs are actively secreted by live cells and could represent a new type of intercellular messenger [531-535].

In fact, once in the extracellular environment, exosomes and MVs could participate in a wide variety of physiological as well as pathological processes. The functions of EMVs are the result of their interactions with recipient cells and are related to their cargo and to their structural and biochemical properties, which, in turn, depend on their source of origin [378, 536]. Several modes of interaction of EMVs with target cells have been proposed. EMVs may dock at the plasma membrane of recipient cells through lipids or ligands-receptor interactions [537] (Figures X-d and XIV-a). For example, intracellular adhesion molecule 1 (ICAM1)-bearing exosomes secreted from mature DCs are captured by CD8+ DCs with help of lymphocyte function-associated antigen 1 (LFA-1) [538] (Figure X-c). Similarly, galectin-5 participates in the recruitment of reticulocyte exosomes by macrophages [539].

The binding is followed by different events. First, at this location MVs can establish a reaction platform, thus inducing the extracellular assembly of functional multimolecular complexes and the coordinate development of multi-signaling processes [540, 541]. Second, EMVs can directly fuse with the plasma membrane of target cells, resulting in the integration of their membrane proteins into the membrane of recipient cells and the release of their cargo into the cytoplasm (Figures X-d and XIV-b). Third, vesicles can be internalized by endocytosis [378, 542] (Figure XIV-c). This event can be followed by: the fusion of endocyted vesicles with the limiting membrane of the endosome, which causes the release of vesicles contents into the cytoplasm and the incorporation of the membrane proteins into the endosomal membrane, which, then, can be redirected to the cell surface (Figure XIV-c-ii); the degradation of vesicles in the phagocytic pathway, which, for example, can lead to the production of antigenic peptides and their presentation onto MHC class II and I molecules at the cell surface [378, 407] (Figure XIV-c-iii); transcytosis, in fact, it has been documented that, at least MVs, once segregated within endosomes, can be released intact back to the extracellular space [407] (Figure XIV-c-i).

In addition, upon release from their cell of origin, vesicles could not remain intact for long, but broken down and release their contents in the extracellular environment, thus depositing paracrine signals.
For example, shedding vesicles derived from tumor cells release MMPs and their inducer (CD147 or EMM-PRIN, extracellular matrix metalloproteinases inducer), that, through the degradation of ECM, promote the motility of malignant cells, which become capable to invade tissues more quickly [543-545]. The vesicles shed from neurons, astrocytes, hepatocarcinoma and endothelia, instead, release FGF2 [428, 429, 546]. Taraboletti et al. showed that EVMs derived from ovarian carcinoma cell lines burst is promote when the extracellular pH is acidic [547]. Further, this mechanism allows the regulated release by cells of proteins deprived of signal sequences, which, for this reason, can not enter the classical secretory pathway [407].

It also has been observed that vesicles secretion could be used to eliminate proteins resistant to lysosomal degradation. For example, during the process of red blood cell maturation, reticulocyte releases exosomes to remove membrane proteins no more necessary for its function, such as transferrin receptor [548].

Given that most of EMVs studies have been performed in vitro or from body fluids, their overall biological relevance remains unclear.

**Figure XIV. Interactions of MVs with their recipient cells.** Once MVs are released by donor cells into the extracellular space they can: bind to the surface of the target cells by specific receptors (a); fuse their membrane with that of recipient cells (b); be internalized by endocytosis (c). This last event can be followed by: transcytosis (i); the fusion of MVs membrane with that of cell endosome (ii); the targeting to lysosome for the degradation of their contents (iii). The arrows indicate the direction of cargo discharge taking place upon vesicles membrane fusion [modified from ref. 407].
EMVs in tumor diseases

Besides the direct cell-cell contact and the secretion of bioactive molecules [549], the communication and the exchange of informations between cancer cells and the activated stroma can be mediated by the release of EMVs [550]. These vesicles contribute to the mutual horizontal transfer of tumor suppressors, phosphoproteins, proteases, growth factors, nucleic acids and bioactive lipids [551], all of which can modulate several phases of tumor progression, such as immune surveillance, inflammation, angiogenesis, thrombosis, invasion, metastasis, chemoresistance and further important biological events [408, 552-561]. Tumor cells may release various forms of membrane vesicles, each one characterized by unique morphological traits and functions [562]. They include exosomes, microvesicles [563] and a particular form of larger particles (called large oncosomes, 1,000-10,000 nm in diameter) which shed from the plasma membrane of certain types of cancer cells during the amoeboid motility [564].

In the tumor microenvironment, tumor-derived vesicles can promote cancer cells survival, aiding the escape from apoptosis as well as from immune surveillance. MVs represent a protective mechanism from cell death because they serve as a means to remove the potentially dangerous caspase 3. In fact, MVs contain considerable amounts of this effector of apoptosis, which, for this reason, is not detectable within the cells [565, 566]. In addition, Shedden et al. showed that chemoresistant cancer cells express more membrane shedding-related genes compared with chemosensitive counterpart, suggesting a link between vesicles secretion and multidrug resistance [512]. The modulation of the immune system activities, instead, is mediated both through the mechanism of “complement resistance” [567] and by the suppression of the immune response. Shedding vesicles can contain the complement inhibitor membrane cofactor protein CD46, which inactivates the complement complex, hence avoiding cell lysis [568], as well as can express immune modulatory molecules. In particular, MVs from different types of cancer cells expose the ligand (FasL, CD95L) of the death receptor Fas (CD95), which induces apoptosis in activated T cells and diminishes their killer activity [569, 570]. Lymphoblastoma-derived microvesicles, instead, express latent membrane protein-I (LMP-I), which inhibits leucocyte proliferation [571]. Vesicles produced by human melanoma or colorectal carcinoma cells are also able to fuse with plasma membrane of monocytes, thus impairing their differentiation to APCs, but promoting the release of immunosuppressive cytokines, whose role is to block cytolytic T-cell activation and function [572].
Further, tumor-derived vesicles can support invasive growth and metastasis of cancer cells with different mechanisms. First, MVs contain and expose proteases, including MMP-2, MMP-9, MT1-MMP, their zymogens, uPA and EMM-PRIN, that, as reported above, degrade numerous components of the ECM, allowing malignant cells to cross the basement membranes [425, 547, 573-575].

Second, tumor cells, but maybe also endothelial cells, monocytes and platelets, can produce procoagulant tissue factor (TF)-bearing MVs [576-578], which perform their function through coagulation-dependent and -independent mechanisms. In the former, TF-bearing MVs begin the intravascular coagulation and lead to fibrin production, which, in turn, can coat tumor cells protecting them from immune detection and attacks, as well as provides the structural support necessary for angiogenesis [579-581]. In the last, TF expressed by vesicles induces the paracrine activation of ECs through a specific class of G-protein-coupled receptors, known as PARs (protease-activated receptors), causing the increased secretion of the pro-angiogenic heparin-binding EGF-like growth factor (HB-EGF) by these cells [582].

Third, tumor-derived vesicles can transfer mutant molecules to non-malignant and normal cells, thereby influencing their phenotype and biological behavior. It has been documented that the vesicles-mediated passage of oncogenic EGF receptor (EGFR or EGFRvIII) from aggressive glioma cells to indolent ones leads to morphological transformation of these recipient cells and increases their anchorage-independent growth capacity [583]. Similar findings were reported by Peinado et al., who found that highly metastatic melanoma produces EMVs containing MET. This tyrosine kinase is able to increase the metastatic behavior of primary tumors by permanently re-educating the recipient bone marrow-derived cells (BMDCs) that, once activated, support the formation of pre-metastatic niches in distant organs [561].

Nucleic acids are also packaged in tumor-derived microvesicles and contribute to the transfer of genetic informations between cells. MVs contain: miRNAs, that may modify the transcriptome of recipient cells promoting tumor progression and metastases, but the mechanisms are not yet completely understood [469, 584-586]; noncoding RNAs (ncRNAs), that are involved in gene regulation at both transcriptional and post-transcriptional levels [587]; retrotransposon RNAs, such as LINE-1, HERV-K and Alu [411], that, by inserting themselves into the genome, can increase its plasticity [588]; cDNAs and genomic DNA derived from DNA replication, although their source is not fully clear [411]; mRNAs that promote tumor growth, invasion, immune repression [469] and angiogenesis [589].
For example, cancer cell-derived MVs can transfer mRNA encoding growth factor (including VEGF and HGF) to monocytes, which then produce these molecules [520, 590].

The protein, lipid and RNA contents of tumor-derived vesicles can be modified by different types of stressors typical of tumor microenvironment, such as hypoxia [591-593], acidosis [594], oxidative stress [595-597], thermal stress [596, 598, 599], radiation [591], shear stress [600] and cytotoxic drugs [601]. Accordingly, thermal and oxidative stresses induce leukaemia/lymphoma T and B to produce exosomes enriched in natural killer group 2, member D (NKGD2) ligands, which decrease the capacity of immune system to kill target cells [596]. Further, the treatment of aggressive B-cell lymphoma cells with chimeric anti-CD20 monoclonal antibody (rituximab) leads to the production of CD20-bearing exosomes, which act by protecting cells from antibody and complement-dependent cytolysis [602].

Melanoma cells cultured in acidic milieu, instead, generate exosomes enriched in ganglioside GM3 and sphingomyelin increasing the rigidity of their membrane. This alteration of lipid composition enables the exosomes to fuse more efficiently with the plasma membrane of recipient cells [594]. As for proteins and lipids, also RNA content seems to be stress-mediated. For example, exposure of breast cancer cells to hypoxia results in secretion of exosomes enriched in miR-210 [593]. However, further analysis will be necessary to elucidate how stress conditions modulate RNA content of tumor-derived vesicles. Intriguingly, alterations in the protein, lipid and RNA composition can cause change in the biological functions of vesicles, but their impact on tumor development needs to be clarified [603].

Besides cancer cells, the activated stroma (macrophages, fibroblasts and platelets) may release EMVs into the tumor microenvironment [551]. In particular, platelet-derived MVs stimulate mRNA expression of pro-angiogenic factors in cancer cells [598] and, as mentioned above, fibroblasts-derived exosomes induce breast cancer cell migration and invasiveness through the Wnt-PCP signaling [141].

EMVs released by both cancer and stromal cells can perform their function locally (in the tumor microenvironment), as well as at the systemic level owing to their dissemination through body fluids (such as blood and urine), suggesting that the detection of these vesicles could be used as circulating non-invasive biomarkers not only for the early diagnosis [437, 469], but also in the surveillance of disease progression, and thus for prognosis [605-607]. In addition, EMVs may have other multiple applications. Because the release of vesicles can promote tumor development, the production and secretion processes themselves could also be an interesting target of anti-cancer therapy [608].
Further, EMVs could be used as drug-delivery vehicles [609] or as adjuvant anti-cancer treatment. In fact, cancer cell-derived MVs may facilitate immune attacks by transferring tumor antigens to APCs, which in turns activate T cells [424], alternatively, autologous dendritic cells-derived MVs, which act by triggering cytotoxic T lymphocytes in vivo, may be used as autologous anti-cancer immunotherapy [454, 610-614]. Finally, because the anti-cancer therapy modulates the contents of vesicles, the effectiveness of this treatment can be assessed by analyzing vesicles themselves [615].

**Other functions of EMVs**

EMVs represent a new way of communication shared by an increasing number of cell types. In particular, APCs-derived exosomes express MHC-peptide complexes which are able to be directly recognized by their cognate T-cell receptor and activate primed CD4+ and CD8+ T cells [415, 616-618]; on the contrary, exosomes must be captured by DCs to induce the activation of naïve T lymphocytes [619]. This different behavior may depend on the activated conformation of LFA-1 integrin at the surface of DCs and primed (but not naïve) T lymphocytes, which efficiently bind to ICAM1-bearing exosomes [538, 617]. Alternatively, the activation of naïve T cells may require not only the TCR-dependent signal, but also the cytokines secreted by DCs [530]. As with APCs-derived exosomes, those released by B cells display MHC class I and class II, which activate specific T cell responses [451], and functional integrins, that mediate the anchorage to ECM components and to cytokine-activated fibroblasts. For example, exosomes adhesion to TNF-α-activated fibroblasts results in cytosolic calcium changes [620].

In addition, exosomes were secreted by epithelia both from the apical and the basolateral sides of the polarized cell monolayers. Exosomes released at the apical membrane contain specific molecules, such as syntaxin 3, microsomal dipeptidase CD26 and may be involved in a clearance process [451]. Basolateral exosomes, instead, are constitutively enriched in A33 antigen and MHC class II after activation by IFN-γ, and seem participate in antigen presentation [621].

Further, vesicles released from intraocular epithelia in response to inflammation contain the target antigen hr44 and CD63 and have a role in the maintenance of ocular immune privilege [622]. Further, cauda epididymal region produce exosomes [623], known as “epididymosomes”, that participate in sperm epididymal maturation by transferring P25b, a component of a family of sperm surface proteins necessary for the binding to the surface of the egg [451]. Recent reports showed that ECs produce exosomes enriched with miR143/145, which are transferred to
smooth muscle cells (SMCs), influencing gene expression of miRNA target and thus providing atheroprotective properties [624].

Although there are several evidences of the potential biological function of EMVs, to date, most of the studies were performed in vitro or from body fluids and the knowledge about their possible function in vivo is still very little. Furthermore, it is not clear if the amounts of EMVs used in in vitro experiments are comparable to those in vivo. In this regard, only one study was conducted. In 2006, Taylor et al. showed that the serum of women delivering the pregnancies at full term has higher concentration of placenta-derived exosomes compared to women delivering preterm, and that these vesicles express significantly higher levels of biologically active molecules, such as FasL and MHC class II. These vesicles are able to inhibit T cell responses in a CD95L-dependent manner and this inhibition is greater with vesicles obtained from the serum of women delivering at term, suggesting that the function of these vesicles is to prevent the maternal immune response against the fetus [625].
MATERIALS AND METHODS

Cell cultures
Human prostatic cancer cells (PC3 and DU145) and A375 human melanoma cell line were purchased from European Collection of Cell Culture (ECACC). Human dermic fibroblasts (HDFs) are from Invitrogen™ Life Technologies and NIH-3T3 mouse fibroblasts are from Istituto Zooprofilattico Sperimentale della Lombardia e dell’Emilia-Romagna. Healthy (HPFs) and transformed (CAFs) human prostatic fibroblasts were isolated from surgical explantation of patients who signed informed consent in accordance with the Ethics Committee of Azienda Ospedaliera Universitaria Careggi by Prof. Serni of Dipartimento di Medicina Sperimentale e Clinica/Urology (Firenze, Italy). Cells were routinely cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 2 mM glutamine, with penicillin (100 U/mL) and streptomycin (100 µg/mL), and with 10% fetal bovine serum (FBS, Euroclone). Cells were incubated at 37°C in a humidified atmosphere of 5% CO₂-95% air.

Materials
Unless otherwise specified all reagents are from Sigma/Aldrich. Carboxyfluorescein diacetate succinimidyl ester (CFDA-SE), Opti-MEM and Lipofectamine® transfection reagent are from Invitrogen™ Life Technologies. Polyvinylidene difluoride (PVDF) membrane and Immobilon Western Chemiluminescent HRP Substrate are from Millipore. Boyden chambers were purchased from Euroclone. Cocultures separation was performed by MACS MicroBeads and MACS Column Technology patented by Miltenyi Biotec. Apoptosis test is performed by Annexin-V-Fluos staining kit from Roche. Sodium [¹⁴C] bicarbonate, L-amino acids mixture [¹⁴C] and the storage phosphor screen are from Perkin Elmer. 2D Quant kit, Ettan™ IPGphor™ system, IPGphor Cup Loading Strip Holders and the ECL plus immunodetection system were purchased from GE Healthcare, USA. ReadyStrip™ IPG strips were purchased from Bio-Rad. CA IX siRNA, anti-enolase and anti-actin antibodies were purchased from Santa Cruz Biotechnology. Anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and anti-superoxide dismutase 2 (SOD-2) antibodies were from Abcam, anti-β-tubulin was from Sigma/Aldrich, anti-pyruvate kinase M1 (PKM1) was from Proteintech, anti-pyruvate kinase M2 (PKM2) was from Cell Signaling Technology, anti-vimentin was from Thermo, anti-CA IX was from Bioscience Slovakia.
**Proliferation assay**

The proliferation was evaluated using CFDA-SE. Tumor or stromal cells were labeled with the dye at the concentration of 2.5 µM. Then PC3, DU145 or fibroblasts were cultured alone or in coculture for 40 hours. After that the cells were detached, fixed in 3% paraformaldehyde and analyzed by flow cytometry. The fluorescence value obtained was analyzed by ModFit software to estimate the proliferation index.

**Fluorescence analysis of protein transfer**

The transfer of proteins from donor cells to recipient cells was evaluated by using CFDA-SE. Donor cells were labeled with the dye at the concentration of 10 µM and then plated in coculture with recipient cells. For flow cytometry analysis the cells were detached after 24 or 40 hours, fixed in 3% paraformaldehyde and the ability of donor cells to transfer proteins was evaluated by measuring the value of fluorescence intensity increase of recipient cells, which is obtained from the ratio between the fluorescence value of the recipient cells measured after coculture with donor cells and the autofluorescence of recipient cells. In fact, once that CFDA-SE passively diffuses into the cytoplasm of donor cells, intracellular esterases cleave its acetate groups and the probe is converted to the fluorescent ester, called CFSE. CFSE reacts with intracellular amines (including that of proteins) and forms fluorescent conjugates that are retained within the cells. For this reason, when labeled donor cells transfer their proteins to recipient ones, the fluorescence intensity of recipient cells increases, on the contrary, if the passage of fluorescent proteins does not occur, their fluorescence intensity remains close to that of autofluorescence.

For confocal microscopy analysis the coculture was grown on glass coverslips. Immediately after plating and after 6 hours the cells were washed with phosphate-buffered saline (PBS) and fixed in 3% paraformaldehyde for 20 minutes at 4°C. After that, the cells were washed again in PBS, mounted with glycerol plastine and observed by confocal fluorescence microscopy (Leica TCS SP5).

**Analysis of lipid transfer**

The transfer of lipids from donor cells to recipient ones was evaluated by using CellVue®. Donor cells were labeled with the dye according to the manufacturer’s protocol and then plated in coculture with recipient cells on glass coverslips. Immediately after plating and after 6 hours the cells were washed with PBS and fixed in 3% paraformaldehyde for 20 minutes at 4°C. After that, the cells were washed again in PBS, mounted with glycerol plastine and observed by confocal fluorescence microscopy (Leica TCS SP5).
Conditioned media preparation
Tumor cells were grown in starvation medium for 48 hours, after that the medium was recovered, centrifuged at 1,000 xg for 20 minutes to discard cell debris and used to culture fibroblasts for 24 hours. Soon after the activation, fibroblasts were used for the experiments.
Alternatively, CAFs were grown in starvation medium for 48 hours, after that the medium was recovered, centrifuged at 1,000 xg for 20 minutes to discard cell debris and used for the proliferation experiments of tumor cells.

Acidification assay
The pH of the external medium of tumor cells or fibroblasts either in single cultures (2x10^5 cells) or in cocultures (10^5 fibroblasts and 10^5 DU145 or PC3) was determined after 24 hours in DME supplemented with 1 mM sodium bicarbonate (pH 7.6) at atmospheric CO_2.

Cell death determination
10^5 DU145 or PC3 were plated in DME supplemented with 25 mM hepes and 10 mM sodium bicarbonate at pH 6.8, pH 7.4 and pH 8.0 for 40 hours at 5% CO_2. Cells were detached with Accutase and labeled with Annexin-V-Fluos staining kit. The probe was directly detected by flow cytometry analysis.

In vitro 2D tumor migration assay
DU145 cells were grown to confluence, starved overnight at pH 6.8 or pH 8.0 in DME supplemented with 25 mM hepes and 10 mM bicarbonate at 37°C and 5% CO_2. A wound was made with a sterile micropipette tip. Floating cells were removed by washing with PBS and then fresh DME at pH 6.8 and pH 8.0 + 10% FBS was added. Cells were photographed immediately after the wound initiation and after 18 hours using an inverted Nikon Eclipse TS100 microscope (X10 objective) with Nikon Digital Sight camera system.

In vitro 3D tumor migration assays
5x10^4 green fluorescent protein (GFP)-expressing PC3 cells (PC3-GFP) were seeded in the top of Boyden chamber (trans-well migration assay) in serum-free medium alone or in coculture with 5x10^4 fibroblasts, while medium + 10% FBS was placed in the well below in 24-well tissue culture plates. After 18 hours, while the insert was still moist, the non-migratory cells were mechanically removed from the interior of the insert using a cotton swab. Migrated cells were photographed immediately by fluorescence microscopy (Leica TCS SP5).
In addition, PC3 migration was monitored by xCELLigence Real-Time Cell Analyzer (RTCA) DP instrument (Roche Applied Science). 5x10^4 PC3 were plated in serum-free medium into the upper chamber of CIM (cellular invasion/migration)-Plate 16, while medium supplemented with 10% FBS was placed in the well below. As cells migrate from the upper chamber to the bottom one, they contact and adhere to the electronic sensors on the underside of the microporous PET membrane of the Boyden-like chamber, resulting in an increase in impedance. The impedance increase correlates to increasing numbers of migrated cells on the underside of the membrane and is continuously recorded by the RTCA DP instrument. The impedance is displayed as a dimensionless parameter termed “cell index”.

**Cocultures separation**

DU145 or PC3 were labeled with CFDA-SE and then plated in coculture with fibroblasts. For the CA IX expression analysis, after 40 hours cells were detached with Accutase and separated according to the manufacturer's protocol of MACS Column Technology. A fraction of each cell sample was used to determine the separation efficiency by flow cytometry, which detects the percentage of CFDA-SE-labeled tumor cells in fibroblasts sample after separation, and vice versa. The other part of the sample, instead, was lysed with 2-fold concentrated Laemmli electrophoresis buffer [627] without β-mercaptoethanol and bromophenol blue.

For radiolabeling experiments the cells were detached, separated according to the manufacturer’s protocol of MACS Column Technology and the two cell populations recovered were counted with Bürker chamber. After that a fraction of each cell sample was used to determine the separation efficiency by flow cytometry, another fraction was used to measure the radioactivity (CPM, counts per minute) by liquid scintillation counter (Perkin Elmer), and, only for the samples subjected to 2D electrophoresis (2DE), a part was lysed and the proteins were opportunely extracted. The percentage purity of donor and recipient cells after the coculture separation was higher than 98%. The CPM values measured for recipient cells were calculated subtracting the radioactive contamination due to donor cells, and vice versa.

**Analysis of CA IX expression**

Cells were lysed with 2-fold concentrated Laemmli electrophoresis buffer [627] without β-mercaptoethanol and bromophenol blue and protein concentration was evaluated by bicinchoninic acid (BCA) assay. After that, samples were precipitated according to methanol/chloroform protocol [626]. Briefly, for about 150-300 µg of proteins contained in 150 µL of sample were added 600 µL of methanol, 150 µL of
Materials and Methods

chloroform and 450 µL of water, after each addition the sample was mixed by vortexing. Then the sample was centrifuged at 13,500 xg for 10 minutes, discarded the upper phase, kept the white precipitation disc evident between the upper and lower phases, and then 450 µL of methanol was added to the sample. After 10 minutes of centrifugation at 13,500 xg the supernatant was discarded and the pellet was dried in a vacuum centrifuge for 20 minutes. Then, the sample was resuspended in Laemmli electrophoresis buffer [627]. The proteins (40 µg for each sample) were separated by SDS-PAGE, transferred on PVDF membrane by Western blot and probed with anti-CA IX antibody, and with anti-actin antibody as loading control. Immunoblots were incubated in PBS supplemented with 5% bovine serum albumin and 0.05% Tween for 1 hour at room temperature with primary antibody and then in PBS supplemented with 1% bovine serum albumin and 0.05% Tween for 45 minutes with secondary antibody conjugated with horseradish peroxidase (HRP). Development was performed with Immobilon Western Chemiluminescent HRP Substrate and chemiluminescence was detected by UVP (Ultra-Violet Products) Ltd Chemidoc-it 500 Imaging System. Quantitative analysis of the spots was carried out by Kodak MI software.

Purification of membrane vesicles secreted by CAFs

The culture supernatant recovered from radioactively labeled CAFs was centrifuged at 1,000 xg for 20 minutes to discard cell debris. The supernatant was then centrifuged at 10,000 xg for 40 minutes. The pellet was resuspended in PBS and centrifuged again at 10,000 xg for 40 minutes. The supernatant was recovered and centrifuged at 100,000 xg for 90 minutes. The pellet was resuspended in PBS and centrifuged again at 100,000 xg for 90 minutes. Serum present in fibroblasts growth medium was previously deprived of exosomes by centrifugation at 100,000 xg for 90 minutes.

For proliferation experiments, “10,000 xg pellet” was resuspended in starvation medium and used to grow DU145. For electrophoresis and Western blot analysis, instead, both the “10,000 xg pellet” and the “100,000 xg pellet” were suspended in 100 µL of 2-fold concentrated Laemmli electrophoresis buffer [627] (without β-mercaptoethanol and bromophenol blue) and assayed for protein content by the BCA method. 40 µg aliquots from each sample were additioned with β-mercaptoethanol and separated by SDS-PAGE. Subsequently gels were electroblotted onto PVDF membranes for detection or stained with colloidal blue coomassie. The stained gels were dried on a Slab Gel Dryer (Hoefer, model CD
Dried gels and a storage phosphor screen were inserted in an exposure cassette. After a 15 days exposure time, the images were acquired on a Cyclone Storage Phosphor Scanner (Perkin Elmer). The blots were incubated with anti-enolase, anti-β-tubulin, anti-GAPDH, anti-PKM1, anti-PKM2, anti-vimentin, anti-SOD-2 and anti-actin. After incubation with secondary antibodies, the blotting was developed by using the ECL plus immunodetection system and visualized by autoradiography.

**Dynamic Light Scattering analysis**
Membrane vesicles secreted by fibroblasts were purified as previously described, and resuspended in 800 µL of sterile PBS, after that their size distributions were obtained using Zetasizer Nano S Dynamic Light Scattering device and analyzed by the DTS software (Malvern Instrument Ltd). The analysis was performed at 25°C.

**Sodium [¹⁴C] Bicarbonate incorporation**
DU145 were plated in DME supplemented with 25 mM hepes, 10 mM sodium bicarbonate, 20 µM sodium [¹⁴C] bicarbonate (50.8 mCi/mmol) and 10% FBS at pH 8.0 for 24, 48 and 72 hours. The medium was changed every day. The cells were lysed in 2-fold concentrated Laemmli electrophoresis buffer [627] without β-mercaptoethanol and bromophenol blue. Protein concentration was evaluated by BCA assay. CPM values were obtained by scintillation counter (Perkin Elmer).

**[¹⁴C] L-amino acids incorporation**
Fibroblasts were cultured for 72 hours in exosomes-deprived complete medium supplemented with a mixture of [¹⁴C] L-amino acids. After that cells were detached, washed twice in starvation medium by centrifugation at 1,000 xg for 10 minutes, and plated in coculture with tumor cells.

**GC-MS measurements**
DU145 were plated in single culture and in coculture with fibroblasts in a 1:2 ratio in DME supplemented with 25 mM hepes and 25 mM sodium carbonate-[¹³C] (pH 8.0) at 5% CO₂. The medium was changed every day. After 40 hours DU145 cells of single culture and DU145 cells separated from CAFs with MACS Column Technology were lysed in 100% cold (-80°C) ethanol. Ethanol soluble fraction was dried in a vacuum centrifuge. Dried cell extracts were redissolved in 100 µL of ethanol containing 1% acetic acid. The solution was transferred in a microvial, taken to dryness under a gentle stream of nitrogen at room temperature and then derivatized with N-methyl-N-(t-butyldimethylsilyl)trifluoroacetamide in the presence of 1% t-butyldimethylchlorosilane for 2 hours at 80°C.
The samples were analyzed on an Agilent GC-MS system composed by a 7820A gas chromatograph coupled to a 5975B mass spectrometer operating in electron ionization (EI, 70 eV) mode (Agilent Technologies Italy, Cernusco sul Naviglio, Milan, Italy). The system was equipped with an automatic liquid sampler. The column was a DB 5 MS, 20 m, 0.18 mm, 0.18 μm film thickness (J&W, Agilent Technologies); helium was the carrier gas, at 0.7 ml/min constant flow rate. The oven temperature program was as follow: from 150°C to 220°C then at 5°C/min, then at 30°C/min to 310°C, maintained for 3 minutes. The injections were performed in split mode (4:1 split ratio); the injection volume was 1.5 μL. The injector port and transfer line temperatures were 260°C and 280°C, respectively. The ion source operated at 230°C, while the quadrupole temperature was 150°C. Data were acquired in SIM mode and alternating SIM/scan mode. In SIM the fragment ion at m/z (M-57) was recorded for the 12C and mono 13C species in a specific retention time window: for scan acquisition mass spectra were acquired in the range from 40 m/z to 680 m/z. Data were acquired and elaborated using the MSD ChemStation software (version E.01.01.335, Agilent Technologies). The peaks for malate and fumarate from GC-MS signals were integrated, and atom percent excess (13C) values were calculated by comparison with control samples and unlabeled standard solutions. It was not possible to measure the percent enrichment in oxaloacetate because of the low concentration as well as the instability of this substance.

Sample preparation and 2D Electrophoresis

For 2DE, cocultured DU145 and CAFs from eight independent experiments, separated after 6 hours by MACS column technology, were harvested by centrifugation at room temperature. CAFs and DU145 pellets were washed twice in PBS and resuspended in 50 mM Tris-HCl pH 7.0, 1% NP-40, 150 mM NaCl, 2 mM ethylene glycol bis(2-aminoethyl ether)tetraacetic acid, 100 mM NaF containing a cocktail of protease inhibitors. After sonicated briefly, protein extracts were clarified by centrifugation at 14,000 x g for 10 minutes. Proteins were then precipitated following the chloroform/methanol protocol previously described [626] and the pellet was resuspended in 8 M urea, 4% 3-[(3-cholamidopropyl)dimethylammonio] propanesulfonic acid (CHAPS), and 20 mM dithiothreitol (DTT). The protein content was determined by using the 2D Quant kit. For each cell lysate sample, four 2DE replicate gels were made for each sample, in order to assess biological and analytical variation. The first dimension (isoelectric focusing, IEF) was carried out on ReadyStrip™ IPG strips, pH 3-10 NL (Bio-Rad) and achieved using the Ettan™ IPGphor™ system. IPG-strips were rehydrated with 350 μL of lysis buffer and 2%
v/v carrier ampholyte, for 12 hours at room temperature. Sample load, 800 µg per strip, was successively performed by cup loading in the IPGphor Cup Loading Strip Holders, with the sample cup system at the anodic side of IPG strips. IEF was then achieved at 20°C according to the following voltage steps: 30 V for 30 minutes, 200 V for 2 hours, 500 V for 2 hours, from 500 to 3500 V in 30 minutes, 3500 V for 5 hours, from 3500 to 5000 V in 30 minutes, 5000 V for 4 hours, from 5000 to 8000 V in 30 minutes, 8000 V until a total of 95 000 V/h was reached. After focusing, prior to the second-dimension separation, IPG strips were equilibrated in equilibration buffer (6 M urea, 75 mM Tris-HCl pH 8.8, 29.3% glycerol, 2% SDS) containing 1% (w/v) DTT for 15 minutes and then in the same equilibration buffer containing 2.5% iodoacetamide for a further 15 minutes. The second dimension was carried out on 9-16% polyacrylamide linear gradient gels (18 cm × 20 cm × 1.5 mm) at 40 mA/gel constant current and 10°C until the dye front reached the bottom of the gel. Protein spots were visualized by colloidal coomassie blue staining. The stained gels were scanned with the Epson Expression 1680 Pro image scanner. Gels containing proteins radiolabeled with 14C-labeled amino acids (both CAFs and DU145 proteins) were dried on a Slab Gel Dryer (Hoefer, model CD 2000). Dried gels and a storage phosphor screen were inserted in an exposure cassette. After an appropriate exposure time (2 days for fibroblasts 2DE gel and 15 days for DU145 2DE gel) the images were acquired on a Cyclone Storage Phosphor Scanner (Perkin Elmer).

**Densitometric analysis of radiolabeled protein spots**

Scanned colloidal coomassie blue images and autoradiographic images relative to gels containing 14C-radiolabeled proteins were analysed by the ImageMaster 2D Platinum software (GE Healthcare, USA). Only 10 protein spots present in all the replicates of both fibroblasts and DU145 gels were taken into consideration for subsequent analysis. The relative spot volume (V) was calculated as %V of the total volume of 10 selected spots in each gel, corresponding to 14C-radiolabeled proteins. The normalized %V of the 10 spots on three replicate 2D gels was averaged and the standard deviation was calculated.

**In-gel digestion and MALDI-TOF analysis**

24 protein spots, corresponding to radiolabeled proteins transferred from CAFs to DU145 tumor cells, were manually excised from the 2DE gel in which were separated the proteins isolated from the cocultured DU145 cells. Samples were transferred to a 1.5-mL Eppendorf tube, washed, reduced, carbamidomethylated and treated with a trypsin solution (Trypsin Proteomics Sequencing Grade)
according a modified protocol from Shevchenko et al [628]. Briefly: protein spots were manually excised from gels, washed in 50 mM ammonium bicarbonate (NH₄HCO₃)/CH₃CN 1/1, de-hydrated in CH₃CN and dried. Prior to proteolytic digestion, cysteine residues in proteins were reduced in 10 mM DTT for 30 minutes at 56°C and then alkylated for 30 minutes in the dark with 55 mM iodoacetamide in 25 mM NH₄HCO₃. Gel particles were then washed, de-hydrated and dried. Each sample was finally incubated 1 hour at 37°C in 20 µL of 20 µg/ml trypsin solution (Trypsin Proteomics Sequencing Grade) in 40 mM NH₄HCO₃ with 10% CH₃CN. An additional 30 µL of 40 mM NH₄HCO₃ with 10% CH₃CN were added to each sample and incubated over night at 37°C. The reaction was stopped adding a final concentration of 0.1% trifluoroacetic acid. The supernatant was collected and the gel was further extracted with 0.1% trifluoroacetic acid in 50% CH₃CN. The extracts were combined and then analysed on a MALDI-TOF/TOF mass spectrometer Ultraflex III (Bruker Daltonics, Bremen, Germany) by using Flex Control 3.0 as data acquisition software. A 0.75 µL volume of the sample was mixed to 0.75 µL of the matrix (saturated solution of α-cyano-4-hydroxycinnamic acid in 50% (v/v) CH₃CN and 0.5% (v/v) TFA) on the anchorchip target plate and allowed to dry. Spectra were acquired in reflectron mode over the m/z range 860-4000 for a total of 500 shots. The instrumental parameters were chosen by setting the ion source 1 at 25 kV, ion source 2 at 21.5 kV, the pulsed ion extraction at 20 ns and the detector gain at 7.7x. The instrument was externally calibrated prior to analysis using the Bruker Peptide Calibration standard kit. All the resulting mass lists were cleaned up from eventually present contaminant masses, such as those from matrix, autodigestion of trypsin and keratins. Mass fingerprinting searching was carried out in Swiss-Prot databases using MASCOT (Matrix Science Ltd., London, U.K., http://www.matrixscience.com) software. The taxonomy was restricted to homo sapiens, a mass tolerance of 50 ppm was allowed, and the number of accepted missed cleavage sites was set to one. Alkylation of cysteine by carbamidomethylation was assumed as fixed modification. The experimental mass values were monoisotopic. No restrictions on protein molecular weight and pl were applied. The criteria used to accept identifications included the extent of sequence coverage, number of matched peptides and probabilistic score sorted by the software.
Capillary-LC-µESI-MS/MS

Each peptide mixture was submitted to capillary-LC-µESI-MS/MS analysis on an Ultimate 3000 HPLC (Dionex, San Donato Milanese, Milano, Italy) coupled to a LTQ Orbitrap mass spectrometer (Thermo Fisher, Bremen, Germany). Peptides were concentrated on a precolumn cartridge PepMap100 C18 (300 μm i.d. × 5 mm, 5 μm, 100Å, LC Packings Dionex) and then eluted on a homemade capillary column packed with Aeris Peptide XB-C18 phase (180 μm i.d. × 15 cm, 3.6 μm, 100Å, l/min. The loading mobile (Phenomenex, Torrance, CA, USA) at 1 phases were: 0.1% TFA in H₂O (phase A) and 0.1% TFA in CH₃CN (phase B). The elution mobile phases composition was: H₂O 0.1% formic acid/CH₃CN 97/3 (phase A) and CH₃CN 0.1% formic acid/ H₂O 97/3 (phase B). The elution program was: 0 minute, 4% B; 10 minutes, 40% B; 30 minutes, 65% B; 35 minutes, 65% B; 36 minutes, 90% B; 40 minutes, 90% B; 41 minutes, 4% B; 60 minutes, 4% B. Mass spectra were acquired in positive ion mode, setting the spray voltage at 2 kV, the capillary voltage and temperature respectively at 45 V and 200°C, and the tube lens at 130 V. Data were acquired in data-dependent mode with dynamic exclusion enabled (repeat count 2, repeat duration 15 seconds, exclusion duration 30 seconds) survey MS scans were recorded in the Orbitrap analyzer in the mass range 300-2000 m/z at a 15,000 nominal resolution at m/z = 400; then up to three most intense ions in each full MS scan were fragmented (isolation width 3 m/z, normalized collision energy 30) and analyzed in the IT analyzer. Monocharged ions did not trigger MS/MS experiments. The acquired data were searched with Mascot 2.4 search engine (Matrix Science Ltd., London, UK) against the SwissProt database. The taxonomy was restricted to homo sapiens. The experimental mass values were monoisotopic. Searches were performed allowing: (i) up to one missed cleavage sites, (ii) 10 ppm of tolerance for the monoisotopic precursor ion and 0.8 mass units for monoisotopic fragment ions, (iii) carbamidomethylation of cysteine as fixed modification and oxidation of methionine as variable modification. The criteria used to accept identifications included the extent of sequence coverage, number of matched peptides and probabilistic score sorted by the software.

Cluster Analysis

The identified proteins were subjected to functional pathway analysis using DAVID database (http://david.abcc.ncifcrf.gov/home.jsp) for better understanding their biological context and hypothesize in which physiological processes they may be involved. UniProt accession numbers of the radiolabeled proteins transferred from CAFs to DU145 tumor cells identified in our study were uploaded and mapped.
against the *homo sapiens* data set to extract and summarize functional annotation associated with individual or group of genes/proteins and to identify gene ontology terms, molecular function, biological process and important pathways for the dataset.

**Small interfering RNA (siRNA) Transfection**

siRNA transfection was performed with Lipofectamine and Opti-MEM to knock-down CA IX gene expression. CA IX siRNA is a pool of three target-specific 19-25 nt siRNAs; a scrambled siRNA was used as control. The cells were used for the experiments the day after the transfection.

**Xenograft experiments**

*In vivo* experiments were performed co-injecting PC3 and fibroblasts knocked down for CA IX gene or non-silenced fibroblasts in 6 to 8 week old male severe combined immunodeficient (SCID)-bg/bg mice (Charles River Laboratories International). Six animals were used per group, which were daily monitored. The tumor size was measured every two or three days by a caliper and the tumor volumes were determined by measuring the length (L) and the width (W) of the tumor and calculating the volume \( V = LW^2/2 \). Animals experiments were conducted in accordance with national guidelines and approved by the ethical committee of *Animal Welfare Office of Italian Work Ministry* and conform to the legal mandates and Italian guidelines for the care and maintenance of laboratory animals.
THE EFFECT OF CA IX CATALYSIS PRODUCTS WITHIN TUMOR MICROENVIRONMENT

AIM OF THE STUDY

The microenvironment of solid tumors is a very complex tissue composed by both cellular and non-cellular components. The major cellular elements include fibroblasts, endothelial and immune cells, which exhibit an altered phenotype induced by cancer cells able to form a permissive and supportive environment for tumor progression [629-631]. In fact, these cells produce a range of molecules representing the non-cellular components that modify tumor stroma, i.e. ECM proteins, proteases, cytokines and growth factors. In particular, many ways in which activated fibroblasts of tumor stroma, known as CAFs [82], support tumor progression has been described: by secreting growth factors (HGF, EGF, b-FGF) and cytokines (SDF-1 and IL-6) leading to the infiltration of immune cells, which, in turns promote de novo angiogenesis helping metastatic spread [150]; by remodeling ECM and thus influencing proliferation, survival and migration of cancer cells [127]; by producing and secreting lactate that is then metabolized by oxygenated tumor cells [632].

In addition to this unusual composition and behavior of tumor stroma, other characteristics that distinguish the tumor microenvironment from the corresponding normal tissue are: high interstitial fluid pressure, low O2 tension and low pH. These alterations are due to a perturbation of the balance between pro- and anti-angiogenic factors (process known as “angiogenic switch”), which leads to the formation of disorganized vasculature with structural and functional abnormalities [633], and thus to a reduced perfusion [212]. Other important factors responsible for tumor hypoxia and acidity are the high metabolic rate of tumor cells, which leads to a massive production of acidic metabolites [254, 259, 260, 275, 320, 339], and the increased diffusion distances between microvessels and tumor cells as result of tumor mass expansion [211]. The hypoxic environment contributes to the metabolic shift of cancer cells metabolism towards glycolysis, with the additional release of lactic acid in the extracellular milieu [326]. The high protons concentration, instead, poses a stress on the cells in that the extracellular acidification can ultimately lead to a decrease in pH. In this condition the control of pH, necessary for cells survival [263], is mediated by different types of pH regulating proteins such as: NHE1, AEAs, NBCs, MCTs and CAs [336].
The mammalian CA family contains 16 different isoforms, 13 of which are enzymatically active. Their main function is the catalysis of the reversible hydration of carbon dioxide to bicarbonate and protons \((\text{CO}_2 + \text{H}_2\text{O} \leftrightarrow \text{HCO}_3^- + \text{H}^+)\). Among them, CA IX is a membrane-bound isoform with the catalytic domain located extracellularly and thus is one of the most important proteins involved in tumor extracellular acidification. CA IX is overexpressed in hypoxic conditions (a very common characteristic in fast growing solid tumors) under tight regulation by HIF-1 and is associated with cancer progression and poor prognosis [634, 635].

The aim of our study was to investigate proliferation and migration of cancer cells in the tumor microenvironment context, in particular by analyzing the effect of stromal CA IX catalysis products in the modulation of these phenotypes. Our experimental model is based on prostatic tumor cells (DU145 and PC3) and prostatic primary fibroblasts (HPFs) that, following activation by cancer cells, acquire the typical CAFs phenotype [121].
RESULTS

Cancer cells proliferation within tumor microenvironment

First, we found that tumor cells kept in hypoxia acidify the extracellular medium more than normoxic cells (Figure 1A-C) and that, in coculture, the protons release in the extracellular medium is greater than the sum of single culture cell proton release (Figure 1B-D). This suggests that the interplay between cancer and stromal cells affects important changes in normal and/or in tumor cells metabolism leading to an “extra” acidification of the medium.

In order to evaluate the ability of CAFs to contribute to tumor growth at physiological (7.4) as well as acidic (6.8) or basic (8.0) pH, DU145 and PC3 were plated and grown for 40 hours in single or in coculture with CAFs at various pHr, using CFDA-SE cytofluorometric assay to measure cell proliferation rate of a given
population in coculture conditions (see Methods). We found that single culture cell proliferation rate of both DU145 and PC3 was significantly decreased at acidic pHe (*Figure 2A-B*), without notable presence of cell death in the pHe range considered (*Table I*). In the presence of CAFs, tumor cells proliferation increases at every pHe value compared to the corresponding single culture (*Figure 2A-B*). However, in coculture, CAFs attenuate the growth inhibition observed in single culture at pH 7.4 compared to pH 8.0, but the negative effect of the lowest pH 6.8 is only partially offset.

**Figure 2. Effect of acidity on tumor cells growth.** DU145 (*A*), PC3 (*B*) and HPFs (*C*) were labeled with CFDA-SE and then plated in single culture and in coculture. The cells were grown at various pHes in DMEM supplemented with 25 mM hepes and 10 mM bicarbonate at 37°C and 5% CO₂. After 40 hours cells were detached and analyzed by flow cytometry. The data show the fold increase of proliferation index calculated on an average of five experiments (*, p < 0.1; **, p < 0.05; ***, p < 0.01).

In addition, the CAFs proliferation rate is significantly greater compared to HPFs one (*Figure 2C*), although the difference is less extensive respect to the reciprocal effect of fibroblasts on cancer cells (*Figure 2A-B*), suggesting that the interplay between cancer cells and fibroblasts is mainly devoted to promote tumor cells proliferation.
**Table I. Cell death analysis of DU145 and PC3 cells.**

<table>
<thead>
<tr>
<th></th>
<th>DU145</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Early Apoptosis (%)</td>
<td>Late Apoptosis (%)</td>
<td>Necrosis (%)</td>
</tr>
<tr>
<td>DMEM pH 8.0</td>
<td>4.3 ± 0.5</td>
<td>0.95 ± 0.1</td>
<td>0.65 ± 0.07</td>
</tr>
<tr>
<td>DME pH 6.8</td>
<td>4.5 ± 1</td>
<td>0.5 ± 0.14</td>
<td>0.24 ± 0.05</td>
</tr>
<tr>
<td>DME pH 7.4</td>
<td>6.1 ± 0.9</td>
<td>1.2 ± 0.2</td>
<td>0.59 ± 0.05</td>
</tr>
<tr>
<td>DME pH 8.0</td>
<td>5.3 ± 0.7</td>
<td>1.6 ± 0.6</td>
<td>0.97 ± 0.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>PC3</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Early Apoptosis (%)</td>
<td>Late Apoptosis (%)</td>
<td>Necrosis (%)</td>
</tr>
<tr>
<td>DMEM pH 8.0</td>
<td>3.5 ± 1</td>
<td>0.2 ± 0.09</td>
<td>0.53 ± 0.05</td>
</tr>
<tr>
<td>DME pH 6.8</td>
<td>4.5 ± 1.4</td>
<td>0.3 ± 0.1</td>
<td>0.65 ± 0.04</td>
</tr>
<tr>
<td>DME pH 7.4</td>
<td>4.7 ± 1.4</td>
<td>0.9 ± 0.3</td>
<td>2.4 ± 1</td>
</tr>
<tr>
<td>DME pH 8.0</td>
<td>4.3 ± 2</td>
<td>1 ± 0.4</td>
<td>2 ± 1</td>
</tr>
</tbody>
</table>

Tumor cells were grown in DMEM (pH 8.0) and at various pH in DME supplemented with 25 mM hepes and 10 mM bicarbonate at 37°C and 5% CO₂. After 40 hours cell death determination was performed by staining cells with Annexin-V-Fluos and flow cytometry analysis.

**Figure 3. Effect of acidity on tumor cells growth in hypoxic condition.** DU145 (A-B) or PC3 (C-D) cells were labeled with CFDA-SE and then plated in single culture and in coculture with fibroblasts in a 1:2 ratio at 1% O₂ and at 20% O₂. The cells were grown at various pH in DME supplemented with 25 mM hepes and 10 mM bicarbonate at 37°C and 5% CO₂. After 40 hours the cells were detached and analyzed by flow cytometry. The data show the proliferation index calculated on an average of six experiments (*, p < 0.1; **, p < 0.05; ***, p < 0.01).
In order to assess the effect of extracellular acidity in environmental conditions more similar to in vivo condition, we compared the growth rate of both PC3 and DU145 cells kept at 1% O2 at various pHe. Our results show that hypoxic conditions induce a significant increase in tumor cells growth rate compared to tumors kept at 20% O2 (Figure 3A-C). Nevertheless, in hypoxia we observed a pH dependence cell growth similar to the normoxic conditions, and the same, strong, pro-proliferative effect exerted by CAFs on cancer cells proliferation (Figure 3B-D).

**Bicarbonate ion contributes to cancer cells proliferation**

The bicarbonate buffering system is essential to ensure the homeostasis of both pH and pHe. The CO2 reversible hydration is catalyzed by both intra- and extracellular CAs. In particular, extracellular CAs are involved in extracellular acidification as well as in bicarbonate production. As shown in Figures 2 and 3, a high concentration of H+ ions has negative effects on cancer cells proliferation. Thus, we investigated the possible involvement of the other product of CO2 hydration, i.e. bicarbonate, in tumor cells growth.

**Figure 4. Effect of bicarbonate on DU145 tumor cells growth.** DU145 were labeled with CFDA-SE and then plated in single culture (A), in coculture with fibroblasts in a 1:2 ratio (C) or both (B). The cells were grown at various pHe in DME supplemented either with 25 mM hepes and 10 mM bicarbonate at 37°C and 5% CO2 or in DME supplemented only with 25 mM hepes at 37°C in CO2/bicarbonate free environment. After 40 hours cells were detached and analyzed by flow cytometry. The data show the proliferation index calculated on an average of four experiments (**, p < 0.05).
Therefore we compared the growth rate of tumor cells at 5% CO$_2$ (which corresponds to CO$_2$ pressure present in peripheral tissues) in bicarbonate buffer, with that kept in CO$_2$-free environment (i.e. at atmospheric CO$_2$ concentration, 0.032% CO$_2$). Our results show that in single cultures the proliferation index of tumor cells (DU145 and PC3) is similar in both conditions, therefore bicarbonate does not influence cells growth rate (Figures 4A-5A).

**Figure 5. Effect of bicarbonate on PC3 tumor cells growth.** PC3 were labeled with CFDA-SE and then plated in single culture (A), in coculture with fibroblasts in a 1:2 ratio (C) or both (B). The cells were grown at various pHe in DME supplemented either with 25 mM hepes and 10 mM bicarbonate at 37°C and 5% CO$_2$ or in DME supplemented only with 25 mM hepes at 37°C in CO$_2$/bicarbonate free environment. After 40 hours cells were detached and analyzed by flow cytometry. The data show the proliferation index calculated on an average of four experiments (**, p < 0.05; ***, p < 0.01).

In cocultures, instead, we found a different behavior in the two tumor cell lines. For DU145, we did not observe any difference in growth rate between single culture and coculture in CO$_2$-free environment (Figure 4B), while CAFs exerted a powerful pro-proliferative effect in the presence of 5% CO$_2$/bicarbonate buffer (Figure 4C). In this condition about 90% of the increase in growth rate in the presence of CAFs is due to the presence of bicarbonate for each pH value considered (Table II). For PC3 cells, instead, the increase in growth rate due to the presence of CAFs occurs partly also in CO$_2$-free environment (Figure 5B), bicarbonate being responsible only for about 30% of the overall growth rate increase in coculture (Figure 5C and Table II).
**Table II. Relative contribution of bicarbonate to DU145 and PC3 growth rate increase in coculture.**

<table>
<thead>
<tr>
<th>Relative contribution of bicarbonate in DU145 growth rate increase in coculture (%)</th>
<th>$5% \text{ CO}_2 + 10 \text{ mM HCO}_3^-$</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH 6.8</td>
<td>82%</td>
</tr>
<tr>
<td>pH 7.4</td>
<td>100%</td>
</tr>
<tr>
<td>pH 8.0</td>
<td>89%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Relative contribution of bicarbonate in PC3 growth rate increase in coculture (%)</th>
<th>$5% \text{ CO}_2 + 10 \text{ mM HCO}_3^-$</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH 6.8</td>
<td>1%</td>
</tr>
<tr>
<td>pH 7.4</td>
<td>25%</td>
</tr>
<tr>
<td>pH 8.0</td>
<td>38%</td>
</tr>
</tbody>
</table>

The relative contribution of CO$_2$/bicarbonate was calculated taking into account the relative DU145 and PC3 growth rate increase in the presence or in the absence of CO$_2$/bicarbonate in the same conditions.

Hence, whereas CAFs contribution to DU145 proliferation is essentially due to bicarbonate, PC3 cells largely depend on CAFs for their cell growth, but bicarbonate is not the main factor that contributes to this effect. In order to gain information on the use of bicarbonate by cancer cells we performed experiments with $^{14}$C-bicarbonate that demonstrate the time-dependent organication of bicarbonate (Figure 6). In addition, by using $^{13}$C-bicarbonate and GC-MS, we found an increased steady state of DU145 intracellular $^{13}$C-fumarate and $^{13}$C-malate isotopes when they are grown in coculture with CAFs compared to single DU145 culture (Table III). This evidence indicates an increase in the bicarbonate organication flux in highly proliferative conditions.

![Figure 6](image)

**Figure 6. Bicarbonate organication.** DU145 were cultured in DME supplemented with 25 mM hepes, 10 mM sodium bicarbonate, 20 µM sodium bicarbonate [$^{14}$C] and 10% FBS at pH 8.0 for 24, 48 and 72 hours. The data show the CPM (counts per minute) value normalized on protein concentration of each sample, calculated on an average of three experiments.
The role of stromal cells CA IX in promoting cancer cells growth

DU145 cells growth was significantly fostered in coculture condition exclusively in presence of bicarbonate/CO$_2$ buffering system, hence we determined the expression level of CA IX, the main responsible for extracellular bicarbonate production, in DU145 and in fibroblasts in single culture and after 40 hours of coculture at 1% and 20% O$_2$ followed by MACS separation of the two cellular populations.

<table>
<thead>
<tr>
<th>Isotopic analysis by GC-MS.</th>
<th>13C/12C (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DU145</td>
</tr>
<tr>
<td>MALEATE</td>
<td>35.068 ± 0.518</td>
</tr>
<tr>
<td>FUMARATE</td>
<td>24.504 ± 0.239</td>
</tr>
</tbody>
</table>

Isotopic 13C/12C ratio of malate and fumarate extracted from DU145 single culture and from DU145 cells separated after being cocultured 40 hours with CAFs. Statistical analysis was performed on the basis of three independent experiments.

Figure 7. Analysis of CA IX expression in single culture and in coculture. DU145 and fibroblasts were plated in single culture and in coculture in a 1:2 ratio for 40 hours at 20% O$_2$ (A) and 1% O$_2$ (B). Similarly, PC3 and fibroblasts were plated in single culture and in coculture in a 1:2 ratio for 40 hours at 1% O$_2$ (C). After that, the cocultures were detached and separated by MACS Column Technology. The samples were lysed in Laemmli electrophoresis buffer and used for Western blot analysis. The membranes were treated with anti-CA IX and anti-actin antibodies. Lanes 1 and 2: HPFs and DU145 or PC3 in single culture. Lanes 3 and 4: CAFs and DU145 or PC3 after coculture and separation. The graph shows spots quantification (D).
We observed that CA IX expression in single culture is low both at 1% O\textsubscript{2} and 20% O\textsubscript{2}, while it greatly increases only in CAFs after 40 hours of coculture with DU145 at both O\textsubscript{2} tensions (Figure 7A-B). PC3 were less dependent on bicarbonate for their growth in coculture (Figure 5C and Table I), accordingly we observed a reduced induction of stromal CA IX expression due to PC3 presence (Figure 7C-D) compared to that observed after activation of fibroblasts with DU145 (Figure 7A-B).

In order to assess the role of CAFs CA IX in promoting cancer cells growth, we silenced stromal CA IX and measured DU145 growth rate in coculture conditions. Our results (Figure 8A-B) show that CAFs knocked down for CA IX are far less able to support cancer cells proliferation respect to non-silenced counterpart. In fact, the growth rate of DU145 in presence of CAFs knocked down for CA IX decreases both at 1% O\textsubscript{2} and at 20% O\textsubscript{2} and gets close to that of the single culture.

**Figure 8. Effect of fibroblasts CA IX down-regulation on tumor cells proliferation.** DU145 were labeled with CFDA-SE and then plated in single culture and in coculture with fibroblasts knocked down for CA IX gene or non-silenced, in a 1:2 ratio at 20% O\textsubscript{2} (A) and 1% O\textsubscript{2} (B). After 40 hours cells were detached and analyzed by flow cytometry. The data show the proliferation index calculated on an average of four experiments (**, p < 0.05, ***, p < 0.01; ****, p < 0.005). Western blot images show the analysis of CA IX expression in non-silenced or knocked down fibroblasts at 20% O\textsubscript{2} (A) and 1% O\textsubscript{2} (B).
Further, to assess the role of stromal CA IX in promoting in vivo tumor growth, we co-injected PC3 cells and CAFs (1:5 ratio) in the lateral flanks of SCID-bg/bg mice and we observed that fibroblasts knock-down for CA IX are less able to sustain tumor mass growth compared to control experiment with non-silenced fibroblasts (Figure 9). Linear regression fitting on these data shows that tumor volume growth rate is about three times lower in presence of CAFs defective for CA IX expression compared to wild type ones.

![Figure 9. Silencing of CA IX in fibroblasts decreases tumor growth rate.](image)

**Cancer cells migration within tumor microenvironment**

In order to evaluate the role of stromal CA IX in the modulation of cancer cells motility, PC3-GFP were plated in single culture or in coculture with CAFs silenced or not for CA IX (Figure 10). The fluorescent migrated PC3 were observed by fluorescence microscopy. We found that CAFs increase PC3 motility and part of this effect is mediated by stromal CA IX expression. In fact, CAFs knocked down for CA IX are far less able to promote cancer cells migration with respect to non-silenced counterpart. Therefore, in coculture with CA IX-silenced fibroblasts, the number of migrating PC3 cells decrease and becomes similar to that of single culture (Figure 10). This result reveal a correlation between stromal CA IX and migration of tumor cells, thus we analyzed the effect of CA IX catalysis products, protons and bicarbonate, in the regulation of tumor cells migratory phenotype. First, we investigated the effect of high protons concentration on cancer cells migration. In this regard, we evaluated migratory capacity of tumor cells at acidic (6.8) and basic pH (8.0). Remarkably, single culture cell migration capability of both PC3 (Figure
and DU145 (Figure 12) is greater at basic rather than at acidic pH, without notable presence of cell death in the pH range considered (Table I). In particular, real-time monitoring of PC3 migration shows that the number of migrated cells is quantitatively higher at basic rather than at acid pH (Figure 11). Similarly, wound healing test performed with DU145 cell line shows that, although both pH value lead to the acquisition of the migratory phenotype with an elongated shape, after 18 hours at pH 8.0 cells repaired the wound, instead, at pH 6.8 this action did not occur (Figure 12).

**Figure 10. Effect of fibroblasts CA IX down-regulation on PC3 migration.** PC3-GFP were plated in the upper chamber in serum-free medium, while medium supplemented with 10% FBS was placed in the well below. Migration assay was performed in single culture and in coculture with fibroblasts knocked down for CA IX gene or non-silenced, in a 1:1 ratio. After 18 hours PC3-GFP migrated through the pores, to the other side of the membrane were observed by fluorescence microscopy and counted. The data show the number of migrated cells calculated on an average of three independent experiments (****, p < 0.005). Western blot image show the analysis of CA IX expression in non-silenced or knocked down fibroblasts.

**Figure 11. Effect of acidity on PC3 migration.** PC3 were plated in the upper chamber at pH 6.8 and pH 8.0 in serum-free DME supplemented either with 25 mM hepes and 10 mM bicarbonate at 37°C and 5% CO₂, while media at the same pH supplemented with 10% FBS were placed in the well below. PC3 migration was monitored by xCELLigence Real-Time Cell Analyzer (RTCA) DP instrument.
In order to evaluate the ability of CAFs to support PC3 motility at acidic as well as at physiological (7.4) or basic pH, PC3-GFP were plated in single culture and in coculture with CAFs. We found that CAFs enhance PC3 migration rate compared to the corresponding single cultures (Figure 13). However, the CAFs-mediated increase of PC3 migratory capacity at pH 7.4 and pH 8.0 is considerably higher than that observed at pH 6.8. Therefore, we observed a pH dependence cell migration both in single culture and in coculture. In both conditions, the acidity of the extracellular environment represents a disadvantageous element for the migration process.

Next, we investigated the possible involvement of bicarbonate (i.e. the other product of CO₂ hydration) in tumor cells migration. For this experiment, we compared PC3 migration capability at 5% CO₂ in bicarbonate buffer, with that of cells kept in CO₂-free environment. Our results show that single culture PC3 motility is similar in both conditions (Figure 14). Also the migration rate of PC3 cocultured with CAFs increase in the same extent in CO₂-free environment and in CO₂/bicarbonate buffer, suggesting that bicarbonate produced by stromal CA IX is not involved in the regulation of cell migration (Figure 14).

Figure 12. Effect of acidity on DU145 migration. Confluent monolayers of DU145 cells were starved overnight with DME at pH 6.8 and pH 8.0 supplemented either with 25 mM hepes and 10 mM bicarbonate at 37°C and 5% CO₂. After that they were wounded and allowed to migrate. The wound was photographed at start and after 18 hours.
Figures 13. Effect of acidity on PC3 migration in single culture and coculture conditions. PC3-GFP were plated in the upper chamber at various pH values in serum-free DME supplemented either with 25 mM hepes and 10 mM bicarbonate at 37°C and 5% CO₂; while media at the same pH supplemented with 10% FBS were placed in the well below. Migration assay was performed both in single culture and in coculture with fibroblasts in 1:1 ratio. After 18 hours PC3-GFP cells migrated through the pores to the other side of the membrane were observed by fluorescence microscopy and counted. The data show the number of migrated cells calculated on an average of three independent experiments (**, p < 0.05; ***, p < 0.01).

Figures 14. Effect of bicarbonate on PC3 migration. PC3-GFP were plated in the upper chamber at pH 7.4 in serum-free DME supplemented either with 25 mM hepes and 10 mM bicarbonate at 37°C and 5% CO₂ or in DME supplemented only with 25 mM hepes at 37°C in CO₂/bicarbonate free environment; while medium at the same pH supplemented with 10% FBS was placed in the well below. Migration assay was performed both in single culture and in coculture with fibroblasts in 1:1 ratio. After 18 hours PC3-GFP cells migrated through the pores to the other side of the membrane were observed by fluorescence microscopy and counted. The data show the number of migrated cells calculated on an average of three independent experiments.
**DISCUSSION**

Solid tumors are composed of both highly genetically heterogeneous cancer cells and by numerous kinds of non transformed cells composing the so called tumor microenvironment. The main cellular component of tumor stroma is represented by an activated form of fibroblasts called CAFs. CAFs are widely recognized as key players in cancer progression [82, 636] mainly by sustaining tumor cells survival, proliferation and metastasis. According with these evidences, the emerging idea is that the possibility to counteract tumor progression depends on our understanding of cancer tissue physiology intended as a whole and not simply focusing on cancer cells behavior outside their physiological condition.

In this study we investigated the functional cooperation established between CAFs and tumor cells in the context of the tumor microenvironment, in particular by analyzing the effect of pHe acidification and of CA IX-mediated CO$_2$/bicarbonate fluxes in an *in vitro* coculture model of prostatic tumor. Single culture of HPFs produced less pHe acidification compared to cancer cells (PC3 or DU145) both at 1% O$_2$ and 20% O$_2$ (*Figures 1A and 1C*) according to the common notion that highly proliferating cells, intensifying the glycolytic flux, lead to a strong production and release of acidic equivalents to control their pHi. Surprisingly, PC3-CAFs coculture (*Figure 1D*), as well as DU145-CAFs one (*Figure 1B*), showed a synergistic increment of acidic equivalents production.

The proliferation index determined for each population in single and coculture system suggests: 1) PC3 or DU145 cells proliferation rate in single culture are highly sensitive to environmental pH. Acidic pHe is a stressful condition for tumor cells that leads to a notable reduction of proliferation (*Figure 2A-B*), without presence of cell death (*Table I*); 2) tumor cells, when cocultured with CAFs, show a significant increase in cell proliferation rate at every pHe considered. Nevertheless, the presence of CAFs is not sufficient to completely overcome the negative effect of acidic pHe (*Figure 2A-B*); 3) the transdifferentiation of HPFs to CAFs, induced by their coculture with tumor cells, leads to an increase in fibroblasts proliferation rate (*Figure 2C*), although at a lesser extent compared to that observed for cancer cells (*Figure 2A-B*); 4) hypoxic conditions, commonly found in tumor microenvironment, further contribute to enhance tumor cells proliferation rate both in single culture and in coculture (*Figure 3A-D*). In conclusion, coculture gives a proliferative advantage mainly to cancer cells, particularly in hypoxia, whereas pHe acidification constitutes a negative environmental condition.
One of the proteins responsible for pH acidification in the context of tumor microenvironment is CA IX [255, 304], whose catalytic activity leads to extracellular production of protons and bicarbonate. Given that low pH has a negative impact on both PC3 and DU145 proliferation, we have investigated the role of the other product of CO$_2$ hydration, bicarbonate, in cancer cells proliferation. Summary data reported in Table II show that CAFs-mediated DU145 cells proliferation rate enhancement relies almost totally on bicarbonate presence in the extracellular medium (Figure 4B-C), while only 30% of PC3 cells proliferation increase due to the presence of CAFs is warranted by bicarbonate (Figure 5B-C).

A key question is why bicarbonate does not influence cells proliferation rate in single DU145 and PC3 culture (Figures 4A and 5A). We supposed that bicarbonate concentration sufficient for sustaining single culture cell proliferation can be obtained by atmospheric CO$_2$ or by cell respiration derived CO$_2$. On the contrary, when the growth rate of cancer cells is strongly increased, consequently to CAFs-mediated activation, bicarbonate concentration is the rate limiting ion both for DU145 and PC3 growth. Accordingly, in order to fulfill the demand of bicarbonate there is an up-regulation of stromal CA IX when CAFs are cocultured with cancer cells. Stromal CA IX up-regulation is linked to the extent of bicarbonate contribution to cancer cells proliferation. In fact, we observed a greater CA IX expression increase when CAFs were cultured with DU145 (Figure 7A-B) rather than with PC3 (Figure 7C-D).

It has been shown that bicarbonate may serve as a shuttle to transport protons outside the cell. In this hypothesis, CO$_2$ hydration by extracellular CAs produces protons and bicarbonate, and then the latter is transported within the cell by bicarbonate transporters contributing to cytoplasm alkalization [637, 638] and reforming CO$_2$. Our results, indeed, show that tumor cells also use bicarbonate as a mono carbonic fragment to build biosynthesis intermediates necessary for sustain their high proliferation rate (Figure 6 and Table III) and that this process is enhanced in tumor cells cocultured with activated fibroblasts compared to cancer cells alone as indicated by the increased steady state concentrations of the two Krebs cycle intermediates analyzed (Table III).

The important role of stromal CA IX for sustaining cancer cells growth has been confirmed by siRNA mediated CA IX silencing in CAFs that leads to a remarkable decrease of DU145 proliferation compared to standard coculture conditions (Figure 8A-B). The results of in vitro coculture model are also clearly confirmed by in vivo experiments in which we show that CAFs impaired in CA IX expression lead to a strong reduction of tumor growth (Figure 9).
In summary, these data reveal a new effect of reciprocal interplay between CAFs and tumor cells in the context of the tumor microenvironment mediated by CA IX catalytic activity. In fact, the up-regulation of stromal CA IX induced by cancer cells leads both to the acidification of extracellular milieu and to the production of bicarbonate. While extracellular acidification is disadvantageous for cell proliferation, bicarbonate, through its organication, supplies cancer cells with intermediates useful to sustain their high proliferation rate. It is conceivable that in solid tumors the extracellular acidification could be maintained within acceptable limits by the dynamics of the extracellular fluid, while CA IX activity ensures the amount of bicarbonate sufficient for not constitute a limit to cancer cells growth rate.

Recent study showed that CA IX actively contribute also to cell adhesion and migration, two important steps of metastatic process, which enables tumor cells to escape the primary mass and colonize new body sites where, at least initially, nutrients and space are not limiting. Different ways in which CA IX participates in cell motility has been described: by competing with E-cadherin for the interaction with β-catenin [322]; by leading to disassemble focal adhesion, mainly through inactivation of Rho small GTPase [639]; by co-localizing and physically interacting at the leading edge with bicarbonate transporters NBCe1 and AE2, i.e. the pH regulating cell apparatus of moving cells [357].

Our results show that, not only CA IX expressed by cancer cells, but also that up-regulated in CAFs surface during coculture conditions (Figure 7A-D) promote cancer cells motility. In fact, the increase of cancer cell migration rate observed in coculture is remarkably reduced in presence of CA IX silenced CAFs (Figure 10).

Surprisingly, none of the two CA IX catalysis products have beneficial effect on tumor cells migration either in single culture or in coculture. On one hand, the CO₂/bicarbonate fluxes do not interfere with PC3 migration (Figure 14); on the other one, the extracellular acidity represents an unfavorable condition (Figures 11-12). The negative effect of high protons concentration is not restored in presence of CAFs, and PC3 migration rate remain very low at pH 6.8, instead, significantly increase at pH 7.4 and pH 8.0 (Figure 13).

The migration rate determined for tumor cells both in acidic environment and in the presence or absence of bicarbonate buffer system suggest: 1) the migrating cells of a tumor mass are present at the periphery (invasion front) of the cancer, where the acid/alkaline balance is keep by blood vessels, which remove CO₂ and lactic acid. Conversely, cells of the central tumor region, where acidic waste accumulates, are less able to migrate. This evidence was confirmed by Hlubek et al. [640] who found
that dedifferentiated human colorectal carcinoma cells accumulate the transcriptional activator β-catenin in the nucleus, in contrast to cells of the tumor center; 2) the contribution of stromal CA IX to cancer cells migration is not mediated by its catalysis products, indicating that this CA IX effect could be due to its non-catalytic related function. Besides its role at the cell surface, a very recent study place CA IX among the cell-surface signal transducers undergoing nuclear translocation [641]. Therefore, stromal CA IX could contribute to tumor cells migration by exhibiting a potential intracellular function. Nevertheless, functional aspects of CA IX in tumor cells migration and invasion are still unclear, so future investigations are required.
NEW CONCEPTS ABOUT FIBROBLASTS 
TROPHIC FUNCTION

AIM OF THE STUDY

Fibroblasts are mesenchymal cells with many vital functions both during fetal development and in adult organisms. Their main actions are the production and the continue remodeling of ECM components, which constitute the structural framework, i.e. the connective tissues, of most organs. However, they are also important producers of trophic factors. In fact, fibroblasts, mainly mouse embryonic fibroblasts or MEFs, have been long used as feeder cell layers for the culture and the maintenance of mouse and human embryonic stem cells. In this context, their role is to provide a complex mixture of nutrients, cytokines and growth factors for the long term survival and proliferation of undifferentiated pluripotent stem cells. Fibroblasts, in fact, release various essential growth factors, cytokines and ECM components, such as TGF-β, activin A, laminin-511, and vitronectin [642]. However, not all the secreted molecules are still known and inconsistencies in expression and secretion of these factors make it difficult to determine which components are indispensable [642, 643].

Besides these functions, fibroblasts are also involved in the regulation of epithelial differentiation, in inflammation processes as well as play major roles in wound healing. In fact, they are associated with many diseases, either because implicated in their inception/progression, or because the hyperactivity of these cells can result in excessive production and deposition of ECM components (a process known as fibrosis), determining adverse effect on tissues [72]. Fibroblasts play an essential role in tumor biology representing the major components of tumor associated stroma. These activated fibroblasts are known as CAFs [82]. The transition of a normal fibroblast into an activated one is mediated by growth factors and cytokines secreted by cancer cells. CAFs, in turns, promote neoplastic progression by secreting many cytokines [644, 645]; by releasing lactate that is ultimately uploaded by tumor cells [632]; by producing extracellular bicarbonate through the catalytic activity of their own CA IX [646]; by ECM remodeling; by stimulating inflammation, angiogenesis and lymphangiogenesis [151, 152, 647].

The aim of our study was to investigate the ancillary function of fibroblasts, in particular in the context of the tumor microenvironment. In our experimental model we used non transformed cells, HPFs obtained from surgical explantation of patients, human dermal fibroblasts (HDFs), NIH-3T3 murine fibroblasts, and
malignant cells, including two different human tumor cell lines of prostatic origin (DU145 and PC3) and a human melanoma cell line (A375). The acquisition of the typical CAFs phenotype was obtained by coculturing primary fibroblasts with tumor cells or with their conditioned medium [121].

Since the ability of these cells to secrete soluble signaling molecules has been the subject of various study, we analyzed whether the interplay between fibroblasts and tumor cells could occur through the horizontal transfer of material, in particular of cytoplasmic proteins and membrane lipids.
RESULTS

Fibroblasts transfer proteins and lipids to surrounding cells
In our experimental model, CAFs are able to promote tumor progression by increasing cancer cells proliferation. This analysis was performed by using CFDA-SE cytofluorometric assay to measure tumor cells proliferation rate both in single culture and in coculture conditions (see Methods). Our results show that DU145 (Figure 15A) and PC3 (Figure 15B), increase their growth rate of 30-40% when cocultured with CAFs and of 10-20% when cultured in their conditioned medium, indicating that less than 47% of fibroblasts pro-proliferative effect is mediated by the release of soluble factors or by other form of paracrine intercellular crosstalk.

Always in the context of the tumor microenvironment, we observed that fibroblasts are able to horizontally transfer materials to tumor cells. Confocal microscopy of fibroblasts labeled with CFDA-SE (to follow the transfer of proteins) or with CellVue® (to monitoring the passage of lipids) cocultured with DU145 show that fibroblasts transfer both fluorescent proteins (Figure 16A) and lipids (Figure 16B) to tumor cells in time dependent manner. On the contrary, when DU145, labeled with CFDA-SE or CellVue®, were plated with unlabeled fibroblasts, we did not detect any of the two effects: either the passage of proteins (Figure 16C) or of lipids (Figure 16D).
Figure 16. Confocal microscopy analysis of protein and lipid transfer. Fibroblasts were labeled with CFDA-SE (A) or with CellVue® (B) and then plated in coculture with unlabeled DU145 tumor cells in 2:1 ratio on glass coverslips; in turn, DU145 tumor cells were labeled with CFDA-SE (C) or with CellVue® (D) and then plated in coculture with unlabeled fibroblasts in 2:1 ratio on glass coverslips. Immediately after plating and after 6 hours the cells were fixed in paraformaldehyde and observed by confocal fluorescence microscopy.
Thus, the different capability of protein transfer between CAFs and cancer cells was quantified by a CFDA-SE cytofluorimetric assay in which we measured the fluorescence intensity increase of recipient cells after coculturing with labeled donor cells (see Methods). Our results show that CAFs of prostatic and dermal origin transfer their proteins to tumor prostatic cells (both DU145 and PC3) and to A375, respectively (Figure 17A). On the contrary, the passage of proteins from tumor cells to fibroblasts is notably less (Figure 17A). Besides CAFs, also healthy human fibroblasts derived from the same anatomical sites (HPFs and HDFs) and immortalized, but non transformed, NIH-3T3 murine fibroblasts are able to perform this action (Figure 17B). In order to maintain fibroblasts in a non-activated state these experiments were carried out by using the same stromal cells as recipients. Figure 17B shows that all the types of the tested fibroblasts behave as donor as well as recipient cells, in fact, they transfer proteins to the unlabeled surrounding counterpart.

Figure 17. Flow cytometry analysis of protein transfer. Fibroblasts of prostatic and dermal origin were labeled with CFDA-SE and then plated in coculture in 2:1 ratio with unlabeled prostatic cancer cells (both DU145 and PC3) and A375, respectively; in turns, cancer cells of prostatic origin (both DU145 and PC3) and A375 were labeled with CFDA-SE and then plated in coculture in 2:1 ratio with unlabeled fibroblasts of prostatic and dermal origin, respectively (A). HPFs, HDFs and NIH-3T3 were labeled with CFDA-SE and then plated in coculture in a 2:1 ratio with their unlabeled counterpart (B). After 40 hours (A) or 24 hours (B) cells were detached and analyzed by flow cytometry. The data represent the value of fluorescence intensity increase of recipient cells calculated on an average of three independent experiments (**, p < 0.05; ****, p < 0.001).

Then, we characterized the kinetic aspect of protein transfer, both evaluating the dose- (i.e. the ratio between donor and recipient cells) and the time-dependence. We observed that the amount of transferred proteins increases when the ratio between recipient tumor cells and donor fibroblasts is in favor of the latter (Figure 18A-B), and that the passage of proteins exhibit an increasing trend (Table IV).
The quantitative analysis of the time-course of protein transfer was performed by plating fibroblasts, previously labeled with a mixture of $^{14}$C amino acids, and prostatic cancer cells (DU145 or PC3) in coculture in 2:1 ratio for 6, 16 and 24 hours. After that, the two populations were separated and the respective radioactivity values were measured by liquid scintillation counter (see Methods). The measurement of the radioactivity bound to the proteins transferred from CAFs to tumor cells shows that after 24 hours each fibroblast has transferred about 4.0% of its total protein mass to a DU145 cell and about 9.5% to a PC3 cell (Table IV).

![Figure 18. Kinetic analysis of protein transfer from CAFs to tumor cells.](image)

Fibroblasts of prostatic origin were labeled with CFDA-SE and then plated with DU145 (A) and PC3 (B) both in 2:1 ratio and 1:2 ratio. After 40 hours cells were detached and analyzed by flow cytometry. The data represent the value of fluorescence intensity increase of recipient cells calculated on an average of three independent experiments (*, p < 0.1; **, p < 0.05).

**Table IV. Quantitative analysis of time-course of protein transfer from CAFs to tumor cells.**

<table>
<thead>
<tr>
<th></th>
<th>Percentage of CAFs protein mass transferred to DU145</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>6 hours</td>
<td>16 hours</td>
<td>24 hours</td>
</tr>
<tr>
<td></td>
<td>0.5% ± 0.2</td>
<td>1.9% ± 0.4</td>
<td>4.0% ± 0.4</td>
</tr>
<tr>
<td></td>
<td>Percentage of CAFs protein mass transferred to PC3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 hours</td>
<td>16 hours</td>
<td>24 hours</td>
</tr>
<tr>
<td></td>
<td>0.9% ± 0.3</td>
<td>2.7% ± 0.4</td>
<td>9.5% ± 0.9</td>
</tr>
</tbody>
</table>

The percentage of CAFs protein mass transferred to tumor cells was obtained from the ratio between CAFs radioactivity and that of cancer cell measured for single cell after coculture and separation (CAFs + DU145: “6 hours” vs “16 hours” **, p < 0.05; “16 hours” vs “24 hours” **, p < 0.05; CAFs + PC3: “6 hours” vs “16 hours” **, p < 0.01; “16 hours” vs “24 hours” **, p < 0.01).
In order to test the relevance of this mechanism in the context of the tumor microenvironment, we compared the transfer capability of healthy fibroblasts with respect to CAFs, using healthy stromal cells as recipients. For these experiments, healthy prostatic and dermal fibroblasts were previously grown with the medium conditioned by their respective tumor cells, and thus converted into CAFs. We observed that, although the modulation of this phenomenon depends on the type of tumor cell used for fibroblasts activation, CAFs both of prostatic (Figure 19A) and dermal origin (Figure 19B) transfer a greater amount of proteins compared to their non-activated counterparts. In particular, fibroblasts activated by PC3 increase their potential for protein transfer of about 2.66 fold, instead those activated by DU145 and A375 show an increase of about 1.5 fold (Figure 19A-B).

**Figure 19. Quantitative analysis of protein transfer mediated by healthy fibroblasts and activated ones.** Healthy fibroblasts of prostatic origin (HPFs) and those activated (CAFs) with the medium conditioned by prostatic tumor cells, both DU145 and PC3, were labeled with CFDA-SE and then plated in coculture with unlabeled healthy fibroblasts in a 2:1 ratio in starvation medium (A). Healthy fibroblasts of dermal origin (HDFs) and those activated (CAFs) with the medium conditioned by A375, are labeled with CFDA-SE and then plated in coculture with unlabeled healthy fibroblasts in a 2:1 ratio in starvation medium (B). After 24 hours cells were detached and analyzed by flow cytometry. The data represent the fold increase of the value of fluorescence intensity increase of recipient cells calculated on an average of four independent experiments (**, p < 0.05; ***, p < 0.01). CM, medium conditioned by tumor cells.

**Identification of the proteins transferred from CAFs to tumor cells**

Our next goal was to identify some of CAFs proteins transferred to tumor cells. The approach we have implemented for the comprehensive profiling and identification of the transferred proteins involves the preliminary radiolabeling of fibroblasts proteins. Stromal cells were cultured for 72 hours in a complete medium supplemented with a mixture of $^{14}$C L-amino acids in order to induce their
incorporation into proteins. Therefore, radioactively labeled fibroblasts were plated in coculture with DU145. After 6 hours the two populations were separated, lysed and subjected to 2DE. The representative gels of their protein profile obtained after colloidal coomassie blue staining are displayed on Figures 20A and 20C, instead, Figures 20B and 20D show the corresponding images obtained from the autoradiographies of the same gels after being dried. Figure 20B displays the overall labeling of fibroblasts proteins, while the DU145 autoradiography (Figure 20D) shows limited radiolabeled-protein contents that are proteins derived from CAFs. The degree of purity of DU145 isolated after coculture (see Methods), in fact, is sufficiently high to exclude that the radioactive signal is due to fibroblasts contamination.

![Colloidal Coomassie Staining and 14C Autoradiography](image)

**Figure 20. Proteomic analysis of CAFs and DU145 after coculture and separation.** Radioactively labeled CAFs were cocultured with DU145, after 6 hours the two populations were separated and subjected to 2DE. The figures show the representative gels of their protein profile after colloidal coomassie blue staining (A-C), and display the corresponding images obtained from the autoradiographies of the same gels after being dried (B-D).
The image analysis and the determination of the specific radioactivity of some transferred proteins both in DU145 and in CAFs, further enabled to strengthen our hypothesis. We carried out the quantitative analysis of 10 protein spots selected among the radiolabeled proteins in DU145 by using the ImageMaster 2D Platinum software. These 10 spots were selected for their quality, in fact they are well separated from the surrounding ones, compact and non-saturated. The analysis was done on both the images related to the stained gels and on autoradiographies.

For each protein spot we determined the relative spot volume (V) calculated as %V with respect to the total volume of the 10 selected spots. The normalized %V of each spot on replicate 2D gels was averaged and the standard deviation was calculated (*Table V*). The mean values obtained for the “Prot” (calculated on the spots of coomassie stained gels) and for the “$^{14}$C-Prot” (calculated on $^{14}$C spots of the autoradiographies) were used to calculate the specific relative radioactivity of each spot, both in DU145 and in CAFs gels (%V “$^{14}$C-Prot”/%V “Prot”). *Table VI* shows the results. The specific enrichment calculated for the 10 spots highlights that a selective and specific protein transfer from CAFs to DU145 has occurred.

### Table V. Quantitative analysis of $^{14}$C labeled transferred proteins.

<table>
<thead>
<tr>
<th>SPOT N°</th>
<th>Protein name</th>
<th>% V-DU145 (Prot)</th>
<th>% V-DU145 ($^{14}$C-Prot)</th>
<th>% V-CAFs (Prot)</th>
<th>% V-CAFs ($^{14}$C-Prot)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Thioredoxin</td>
<td>6.48 ± 1.01</td>
<td>9.21 ± 0.87</td>
<td>9.48 ± 0.96</td>
<td>6.28 ± 0.81</td>
</tr>
<tr>
<td>2</td>
<td>Galectin-1</td>
<td>3.51 ± 0.05</td>
<td>12.22 ± 0.07</td>
<td>16.39 ± 0.14</td>
<td>25.09 ± 0.09</td>
</tr>
<tr>
<td>7</td>
<td>Superoxide dismutase (mitochondrial)</td>
<td>2.31 ± 0.05</td>
<td>8.43 ± 0.08</td>
<td>8.59 ± 1.04</td>
<td>5.17 ± 0.98</td>
</tr>
<tr>
<td>8</td>
<td>Triosephosphate isomerase</td>
<td>8.61 ± 0.96</td>
<td>6.15 ± 0.88</td>
<td>6.35 ± 0.31</td>
<td>4.42 ± 0.27</td>
</tr>
<tr>
<td>9</td>
<td>Phosphoglycerate mutase 1</td>
<td>7.09 ± 0.05</td>
<td>4.75 ± 0.04</td>
<td>1.80 ± 0.1</td>
<td>1.9 ± 0.11</td>
</tr>
<tr>
<td>10</td>
<td>Glyceraldehyde-3-phosphate dehydrogenase</td>
<td>6.91 ± 0.07</td>
<td>4.55 ± 0.08</td>
<td>8.83 ± 1.75</td>
<td>6.39 ± 1.22</td>
</tr>
<tr>
<td>14</td>
<td>Malate dehydrogenase (cytoplasmic)</td>
<td>2.77 ± 0.26</td>
<td>4.23 ± 0.29</td>
<td>4.85 ± 1.78</td>
<td>1.76 ± 1.88</td>
</tr>
<tr>
<td>16</td>
<td>Vimentin</td>
<td>9.79 ± 1.44</td>
<td>15.79 ± 1.39</td>
<td>18.70 ± 1.85</td>
<td>30.24 ± 2.22</td>
</tr>
<tr>
<td>22</td>
<td>Alpha-enolase</td>
<td>46.87 ± 1.02</td>
<td>31.91 ± 0.95</td>
<td>22.20 ± 2.41</td>
<td>12.71 ± 1.67</td>
</tr>
<tr>
<td>24</td>
<td>Calreticulin</td>
<td>5.63 ± 0.08</td>
<td>2.71 ± 0.06</td>
<td>2.76 ± 0.06</td>
<td>5.99 ± 0.08</td>
</tr>
</tbody>
</table>

The relative spot volume (V) was calculated as %V of the total volume of 10 selected spots in each gel on both the images related to the stained gels (%V “Prot”) and to the autoradiographies (%V “$^{14}$C-Prot”). The resulting values were used to calculate the specific relative radioactivity of each spot and thus the specific enrichment of the corresponding proteins.
We excised from DU145 gels the main 24 radiolabeled proteins and, after tryptic digestion, for each one was produced a peptide mass fingerprint by MALDI-TOF mass spectrometry analysis. Some spots were further analyzed by capillary-LC-µESI-MS/MS. The identification results were summarized in Table VI.

In order to gain insight into biological significance of the identified proteins, they were categorized according to the DAVID bioinformatics tool. Concerning biological processes, the identified proteins were distributed into two main categories. The major biological process, in which 50% of them are involved, is “generation of precursor metabolites and energy”. Another large part (30%), instead, can be grouped in the “cellular component movement” class. The remaining five proteins are not associated with common biological processes, so we classified them as “other” (Figure 21).

### Table VI. Specific enrichment of 14C labeled transferred proteins.

<table>
<thead>
<tr>
<th>SPOT N°</th>
<th>Protein name</th>
<th>Specific Radioactivity (DU145) % V-(14C-Prot) / % V-(Prot)</th>
<th>Specific Radioactivity (CAFs) % V-(14C-Prot) / % V-(Prot)</th>
<th>Specific Enrichment (DU145/CAFs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Thioredoxin</td>
<td>1.42 ± 0.25</td>
<td>0.66 ± 0.08</td>
<td>2.14 ± 0.47</td>
</tr>
<tr>
<td>2</td>
<td>Galectin-1</td>
<td>3.48 ± 0.05</td>
<td>1.53 ± 0.01</td>
<td>2.27 ± 0.04</td>
</tr>
<tr>
<td>7</td>
<td>Superoxide dismutase (mitochondrial)</td>
<td>3.65 ± 0.08</td>
<td>0.60 ± 0.07</td>
<td>6.06 ± 0.76</td>
</tr>
<tr>
<td>8</td>
<td>Triosephosphate isomerase</td>
<td>0.71 ± 0.13</td>
<td>0.69 ± 0.05</td>
<td>1.02 ± 0.2</td>
</tr>
<tr>
<td>9</td>
<td>Phosphoglycerate mutase 1</td>
<td>0.66 ± 0.007</td>
<td>1.05 ± 0.08</td>
<td>0.63 ± 0.052</td>
</tr>
<tr>
<td>10</td>
<td>Glyceraldehyde-3-phosphate dehydrogenase</td>
<td>0.65 ± 0.014</td>
<td>0.72 ± 0.16</td>
<td>0.91 ± 0.21</td>
</tr>
<tr>
<td>14</td>
<td>Malate dehydrogenase (cytoplasmic)</td>
<td>1.52 ± 0.18</td>
<td>0.36 ± 0.07</td>
<td>4.19 ± 0.95</td>
</tr>
<tr>
<td>16</td>
<td>Vimentin</td>
<td>1.61 ± 0.27</td>
<td>1.61 ± 0.19</td>
<td>0.99 ± 0.21</td>
</tr>
<tr>
<td>22</td>
<td>Alpha-enolase</td>
<td>0.68 ± 0.02</td>
<td>0.57 ± 0.09</td>
<td>1.18 ± 0.2</td>
</tr>
<tr>
<td>24</td>
<td>Calreticulin</td>
<td>0.48 ± 0.01</td>
<td>2.16 ± 0.06</td>
<td>0.22 ± 0.008</td>
</tr>
</tbody>
</table>

The specific radioactivity was obtained taking into account the relative spot volume of each protein calculated with respect to the total volume of the 10 selected spots reported in Table V. In turn, the specific enrichment of each protein was obtained from the ratio between the values of specific radioactivity calculated in the two cell populations. **Red:** lowered proteins compared to their contents in CAFs; **Green:** specifically enriched proteins compared to their contents in CAFs.
### Table VII. Protein identification by MALDI-TOF mass spectrometry and capillary-LC-μESI-MS/MS analysis.

<table>
<thead>
<tr>
<th>Spots N°</th>
<th>Accession N°</th>
<th>Protein name</th>
<th>Measured p/Mr (Da)</th>
<th>Theoretical p/Mr (Da)</th>
<th>N° of matched peptides</th>
<th>MASCOT search results</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>P10599</td>
<td>Thioredoxin</td>
<td>4.76/13.25</td>
<td>4.82/12.01</td>
<td>21</td>
<td>83</td>
</tr>
<tr>
<td>2</td>
<td>P09382</td>
<td>Galectin-1</td>
<td>5.21/13.68</td>
<td>5.34/13.05</td>
<td>6</td>
<td>64</td>
</tr>
<tr>
<td>3</td>
<td>Q9EC61</td>
<td>Peptidyl-prolyl cis-trans isomerase A</td>
<td>7.90/17.90</td>
<td>7.68/18.23</td>
<td>9</td>
<td>62</td>
</tr>
<tr>
<td>4</td>
<td>Q9UC61</td>
<td>Peptidyl-prolyl cis-trans isomerase A</td>
<td>7.86/17.79</td>
<td>7.68/18.23</td>
<td>172</td>
<td>86</td>
</tr>
<tr>
<td>5</td>
<td>P2532X</td>
<td>Cotillin-1</td>
<td>8.01/19.92</td>
<td>8.22/19.72</td>
<td>11</td>
<td>65</td>
</tr>
<tr>
<td>6</td>
<td>P06733</td>
<td>Trypsinogen alpha-3</td>
<td>4.66/33.25</td>
<td>4.68/32.86</td>
<td>58*</td>
<td>51*</td>
</tr>
<tr>
<td>7</td>
<td>Q9PF73</td>
<td>Trypsinogen alpha-1</td>
<td>4.67/32.92</td>
<td>4.67/32.62</td>
<td>44*</td>
<td>53*</td>
</tr>
<tr>
<td>8</td>
<td>P06174</td>
<td>Triosephosphate isomerase</td>
<td>7.37/27.99</td>
<td>7.65/31.06</td>
<td>10</td>
<td>45</td>
</tr>
<tr>
<td>9</td>
<td>P18609</td>
<td>Phosphoglucone isomerase</td>
<td>7.33/29.43</td>
<td>6.67/29.90</td>
<td>124</td>
<td>83</td>
</tr>
<tr>
<td>10</td>
<td>P04406</td>
<td>Glyceraldehyde-3-phosphate dehydrogenase</td>
<td>7.69/33.86</td>
<td>8.57/36.20</td>
<td>9</td>
<td>38</td>
</tr>
<tr>
<td>11</td>
<td>P04406</td>
<td>Glyceraldehyde-3-phosphate dehydrogenase</td>
<td>8.57/35.77</td>
<td>8.57/36.20</td>
<td>7</td>
<td>38</td>
</tr>
<tr>
<td>12</td>
<td>P04406</td>
<td>Glyceraldehyde-3-phosphate dehydrogenase</td>
<td>8.57/35.26</td>
<td>8.57/36.01</td>
<td>148</td>
<td>86</td>
</tr>
<tr>
<td>13</td>
<td>P26526</td>
<td>Malate dehydrogenase, mitochondrial</td>
<td>8.92/35.94</td>
<td>8.92/35.94</td>
<td>39</td>
<td>59</td>
</tr>
<tr>
<td>14</td>
<td>P26526</td>
<td>Malate dehydrogenase, mitochondrial</td>
<td>8.92/35.94</td>
<td>8.92/35.94</td>
<td>39</td>
<td>59</td>
</tr>
<tr>
<td>15</td>
<td>P04406</td>
<td>Glyceraldehyde-3-phosphate dehydrogenase</td>
<td>8.97/37.46</td>
<td>8.97/37.46</td>
<td>21</td>
<td>40</td>
</tr>
<tr>
<td>16</td>
<td>P04406</td>
<td>Glyceraldehyde-3-phosphate dehydrogenase</td>
<td>8.97/37.46</td>
<td>8.97/37.46</td>
<td>21</td>
<td>40</td>
</tr>
<tr>
<td>17</td>
<td>P26526</td>
<td>Malate dehydrogenase, cytoplasmic</td>
<td>8.97/37.46</td>
<td>8.97/37.46</td>
<td>21</td>
<td>40</td>
</tr>
<tr>
<td>18</td>
<td>P26526</td>
<td>Malate dehydrogenase, cytoplasmic</td>
<td>8.97/37.46</td>
<td>8.97/37.46</td>
<td>21</td>
<td>40</td>
</tr>
<tr>
<td>19</td>
<td>P07355</td>
<td>Annexin A2</td>
<td>7.73/36.57</td>
<td>7.57/38.81</td>
<td>17</td>
<td>50</td>
</tr>
<tr>
<td>20</td>
<td>Q8NE50</td>
<td>Vimentin</td>
<td>4.67/44.50</td>
<td>5.06/53.68</td>
<td>20</td>
<td>48</td>
</tr>
<tr>
<td>21</td>
<td>Q8NE50</td>
<td>Vimentin</td>
<td>4.50/46.99</td>
<td>5.06/53.68</td>
<td>22</td>
<td>51</td>
</tr>
<tr>
<td>22</td>
<td>Q8NE50</td>
<td>Vimentin</td>
<td>5.07/48.42</td>
<td>5.06/53.68</td>
<td>48</td>
<td>59</td>
</tr>
<tr>
<td>23</td>
<td>Q8NE50</td>
<td>Vimentin</td>
<td>5.18/50.48</td>
<td>5.06/53.68</td>
<td>82</td>
<td>78</td>
</tr>
<tr>
<td>24</td>
<td>Q8NE50</td>
<td>Vimentin</td>
<td>5.18/50.48</td>
<td>5.06/53.68</td>
<td>82</td>
<td>78</td>
</tr>
<tr>
<td>25</td>
<td>Q8NE50</td>
<td>Vimentin</td>
<td>5.18/50.48</td>
<td>5.06/53.68</td>
<td>82</td>
<td>78</td>
</tr>
<tr>
<td>26</td>
<td>P06733</td>
<td>Tubulin beta chain</td>
<td>4.94/50.80</td>
<td>4.94/50.80</td>
<td>15</td>
<td>43</td>
</tr>
<tr>
<td>27</td>
<td>Q8NE50</td>
<td>Vimentin</td>
<td>5.36/52.34</td>
<td>5.06/53.68</td>
<td>47</td>
<td>85</td>
</tr>
<tr>
<td>28</td>
<td>Q8NE50</td>
<td>Vimentin</td>
<td>5.36/52.34</td>
<td>5.06/53.68</td>
<td>47</td>
<td>85</td>
</tr>
<tr>
<td>29</td>
<td>Q8NE50</td>
<td>Vimentin</td>
<td>5.36/52.34</td>
<td>5.06/53.68</td>
<td>47</td>
<td>85</td>
</tr>
<tr>
<td>30</td>
<td>P06733</td>
<td>Tubulin beta chain</td>
<td>4.94/50.80</td>
<td>4.94/50.80</td>
<td>15</td>
<td>43</td>
</tr>
<tr>
<td>31</td>
<td>Q8NE50</td>
<td>Vimentin</td>
<td>5.36/52.34</td>
<td>5.06/53.68</td>
<td>47</td>
<td>85</td>
</tr>
<tr>
<td>32</td>
<td>Q8NE50</td>
<td>Vimentin</td>
<td>5.36/52.34</td>
<td>5.06/53.68</td>
<td>47</td>
<td>85</td>
</tr>
<tr>
<td>33</td>
<td>Q8NE50</td>
<td>Vimentin</td>
<td>5.36/52.34</td>
<td>5.06/53.68</td>
<td>47</td>
<td>85</td>
</tr>
<tr>
<td>34</td>
<td>Q8NE50</td>
<td>Vimentin</td>
<td>5.36/52.34</td>
<td>5.06/53.68</td>
<td>47</td>
<td>85</td>
</tr>
</tbody>
</table>

*2 missed cleavages

Mass lists were cleaned up from eventually present contaminant masses, such as those from matrix, autodigestion of trypsin and keratins. Mass fingerprinting or MS/MS searching were carried out in Swiss-Prot databases using MASCOT (Matrix Science Ltd., London, U.K., http://www.matrixscience.com) software. The taxonomy was restricted to human and the number of accepted missed cleavage sites was set to one. Alkylation of cysteine by carboxymethylation was assumed as fixed modification. Oxidation of methionine was assumed as variable modification. The experimental mass values were monoisotopic. Mass lists were cleaned up from eventually present contaminant masses, such as those from matrix, autodigestion of trypsin and keratins and a mass tolerance of 50 ppm was allowed for mass fingerprinting searches. A peptide tolerance of 10 ppm and a MS/MS tolerance of 0.6 Da were allowed for MS/MS searches. No restrictions on protein molecular weight and pl were applied. The criteria used to accept identifications included the extent of sequence coverage, number of matched peptides and probabilistic score sorted by the software.
Besides the networks of soluble molecules, it is known that cell-cell communication occurs also through membranous structures, called extracellular vesicles, that horizontally transfer biologically active mediators, including nucleic acids, receptors and enzymes [407-411]. We characterized the extracellular vesicles released by CAFs, and investigated their possible involvement as vehicles in protein transfer process to tumor cells. In this regard, the medium recovered from the culture supernatant of CAFs was centrifuged (see Methods) and two different fractions of vesicles were obtained. In particular, we separated vesicles within 10,000 xg pellet from that within 100,000 xg pellet, which were then examined for their size and content.

The size of these particles was revealed by Dynamic Light Scattering analysis. We found that the fraction within 10,000 xg pellet contains mainly only one population of vesicles with a diameter of about 1 µm (Figure 22A-B), on the contrary, the prevalent population of vesicles within 100,000 xg pellet has a diameter of about 20 nm (Figure 22C-D). Since a uniform nomenclature to define extracellular vesicles has not yet been adopted in the literature, in this study, fibroblasts-secreted vesicles will be classified exclusively in accordance to their size. Thus, for clarity, we will refer to vesicles with a diameter of about 1 µm as microvesicles (MVs), and to vesicles with a diameter of about 20 nm as exosomes like-vesicles.

Figure 21. Functional clustering of the identified proteins. Cluster analysis was performed by using DAVID database. The pie chart shows the resulting functional interpretation.

The role of extracellular membrane vesicles in fibroblasts-tumor cells communication

Besides the networks of soluble molecules, it is known that cell-cell communication occurs also through membranous structures, called extracellular vesicles, that horizontally transfer biologically active mediators, including nucleic acids, receptors and enzymes [407-411]. We characterized the extracellular vesicles released by CAFs, and investigated their possible involvement as vehicles in protein transfer process to tumor cells. In this regard, the medium recovered from the culture supernatant of CAFs was centrifuged (see Methods) and two different fractions of vesicles were obtained. In particular, we separated vesicles within 10,000 xg pellet from that within 100,000 xg pellet, which were then examined for their size and content.

The size of these particles was revealed by Dynamic Light Scattering analysis. We found that the fraction within 10,000 xg pellet contains mainly only one population of vesicles with a diameter of about 1 µm (Figure 22A-B), on the contrary, the prevalent population of vesicles within 100,000 xg pellet has a diameter of about 20 nm (Figure 22C-D). Since a uniform nomenclature to define extracellular vesicles has not yet been adopted in the literature, in this study, fibroblasts-secreted vesicles will be classified exclusively in accordance to their size. Thus, for clarity, we will refer to vesicles with a diameter of about 1 µm as microvesicles (MVs), and to vesicles with a diameter of about 20 nm as exosomes like-vesicles.
The composition of these distinct subtypes of vesicles was examined by SDS-PAGE. Figure 23A shows the representative gel of their protein profile obtained after colloidal coomassie blue staining, instead Figure 23B displays the corresponding image obtained from the autoradiography of the same gel after being dried. We found that both fractions contain radioactive proteins but with a different composition, in particular, MVs are rich in proteins with a molecular weight lower than 58 kDa, on the contrary, exosomes-like vesicles are rich in proteins with a molecular weight greater than about 40 kDa (Figure 23A-B).

In order to determine which subtype of particles was responsible for the passage of the proteins previously identified, we performed the Western blot analysis.
We found that most of the transferred proteins are more abundant in vesicles with a diameter of about 1 µm (Figure 23C), suggesting that MVs are one of the mediators that allow the passage of these biological molecules from CAFs to tumor cells.

**Figure 23. SDS-PAGE and Western blot analysis of the two subpopulations of vesicles obtained from the culture supernatant of CAFs.** The vesicles released by CAFs were lysed in Laemmli electrophoresis buffer and the samples were used for SDS-PAGE. The image shows the gel after colloidal coomassie blue staining (A), and display the corresponding image obtained from the autoradiography of the same gel after being dried (B). The vesicles recovered from the culture supernatant of CAFs were lysed in Laemmli electrophoresis buffer and used for Western blot analysis. The membrane were treated with anti-enolase, anti-β-tubulin, anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH), anti-piiruvate kinase M1 (PKM1), anti-piiruvate kinase M2 (PKM2), anti-vimentin, anti-superoxide dismutase 2 (SOD-2) and anti-actin (C).

Finally, we investigated the possible biological roles of these proteins once they enter into the recipient cells. Considering the pro-proliferative effect mediated by CAFs conditioned medium (Figure 15A-B) and since the transferred proteins have a structural role as well as are mainly associated with the generation of precursor metabolites and energy (Figure 21), we correlated protein transfer with fibroblasts trophic function. In this regard, we found that the proliferation index of DU145 grown with just MVs increases and gets close to that induced by CAFs conditioned medium (Figure 24).
Figure 24. Effect of MVs on tumor cells growth. DU145 were labeled with CFDA-SE and then grown in starvation medium, in starvation medium supplemented with MVs obtained from the culture supernatant of CAFs and in CAFs conditioned medium, respectively. After 40 hours cells were detached and analyzed by flow cytometry. The data show the proliferation index calculated on an average of four independent experiments (****, p < 0.005; *, p < 0.1).
**DISCUSSION**

Fibroblasts in mammals comprise a class of highly heterogeneous cell types; in fact those isolated from different anatomical sites display distinct and characteristic gene-expression patterns, which make these cells poorly defined in molecular terms [72]. Despite these different transcriptional patterns, fibroblasts acquire a fine functional specialization, for all of them based on the secretion of growth factors and ECM components, as well as on the regulation of epithelial differentiation and of inflammation [70, 71, 74]. In this study, we add another function shared by human fibroblasts derived from different anatomical sites and by fibroblasts of murine origin. In particular, we found that healthy human fibroblasts of prostatic and dermal origin and non-transformed NIH-3T3 mouse fibroblasts are able to transfer cytoplasmic proteins to neighbouring cells (Figure 17B).

Fibroblasts maintain this property also in pathological conditions, in particular in the context of the tumor microenvironment. Our results indicate that CAFs are able to horizontally transfer their proteins (Figures 16A and 17A) and lipids (Figure 16B) in time-dependent manner to their respective tumor cells. Intriguingly, the passage of material from tumor cells to fibroblasts is far less extensive or undetectable. In fact, although DU145 transfer proteins to CAFs in a very small extent detectable by flow cytometry (Figure 17A), but not by confocal microscopy (Figure 16C), PC3 and A375 are not able to perform this type of effect (Figure 17A). Besides protein transfer, also the passage of lipids from DU145 to CAFs is very low and not visible by confocal microscopy (Figure 16D). These evidences suggest that protein and lipid transfer represents an ancillary function of fibroblasts, that they execute both in physiological and in pathological conditions, and that, within our tumor microenvironment model, it is mainly unidirectional.

The monitoring of the kinetic aspect showed that the amount of transferred material boosts by increasing the ratio between donors and recipients (Figure 18A-B), and that this passage is time-dependent (Table IV). We quantified that tumor cells accumulate the proteins transferred from CAFs so quickly that after just 24 hours about 4.0% and 9.5% of CAFs total protein mass is transferred to DU145 and PC3, respectively (Table IV). Notably, due to the higher mass of fibroblasts with respect to that of cancer cells, in real terms the proteins received by cancer cells represent a significant fraction of their own overall protein content.

It is known that activated fibroblasts of the tumor stroma are morphologically and functionally different from the quiescent ones, and produce proteases, growth factors, cytokines and enzymes [149]. The finding that CAFs, originated from
healthy prostatic and dermal fibroblasts, transfer a greater amount of proteins to 
neighbouring cells compared to their healthy counterparts (Figure 19A-B), suggests 
that this differential effect could represent another hallmark of CAFs phenotype. All 
the lines of tumor cells analyzed are able to increase fibroblasts potential for 
horizontal protein transfer, but the modulation of this activation depends on the 
type of tumor cell. In fact, despite DU145 and PC3 cell lines are both models of 
prostate cancer, they regulate this phenomenon in different ways. In particular, 
while fibroblasts activated by DU145 increase their transfer ability of 1.54 fold, the 
amount of proteins transferred from PC3-activated fibroblasts is clearly much 
higher (the transfer increase is about 2.66 fold) (Figure 19A). The A375-mediated 
modulation of fibroblasts potential transfer, instead, is similar to that of DU145 
(Figure 19B). Since the functional conversion of fibroblasts was performed with 
tumor cells conditioned medium, our hypothesis is that the different form of 
regulation could be due to a diverse tumor cells secretion profile both in qualitative 
and quantitative terms. The different degree of modulation mediated by prostatic 
cancer cells conditioned medium is consistent with data showed in Table IV, where 
CAF s transferred a greater amount of their total protein mass when cocultured with 
PC3 rather than DU145.

The 2DE analysis of radioactively labeled CAFs and DU145 separated after being 
occultured (Figure 20A-D), allowed us to identified the transferred proteins (Table 
VII) and to discover that this phenomenon is highly specific (Tables V-VI). CAFs 
proteins transferred to DU145 are involved in the generation of precursor 
metabolites and energy, or are structural proteins associated with cellular 
movement (Figure 21). The quantitative analysis of 10 protein spots selected among 
the transferred proteins shows that thioredoxin, galectin-1, SOD-2 (mitochondrial 
isoform) and malate dehydrogenase (cytoplasmic isoform) were specifically enriched, 
while phosphoglycerate mutase 1 and calreticulin were lowered compared to their 
relative content in CAFs, suggesting that protein transfer is a selective and not 
random event (Tables V-VI).

Further, we reveal that CAFs-secreted MVs play a key role as vehicles in this 
particular form of communication. CAFs of prostatic origin are able to produce two 
subtypes of vesicles: the larger ones were prepared from the whole culture 
supernatant by centrifugation at 10,000 xg, have an average diameter of 953.3 ± 
168.8 nm (Figure 22A-B), and are rich in proteins with a molecular weight lower 
than 58 kDa (Figure 23A-B). The smaller ones, obtained by centrifugation at 
100,000 xg, include a population less homogeneous, where the prevailing fraction 
has a diameter of 20 ± 1.252 nm (Figure 22C-D). Surprisingly, these vesicles are
richer in proteins with a molecular weight greater than about 40 kDa (Figure 23A-B), which, given the small size of these vesicles, might correspond mainly to integral membrane proteins.

Our results show that, between the two subtypes of particles, MVs represent a means for the paracrine communication between fibroblasts and tumor cells. They, in fact, contain many proteins previously identified, including SOD-2 (mitochondrial isoform), GAPDH, α-enolase, tubulin, vimentin, M2 splice isoform of pyruvate kinase, and not the M1 isoform which, on the contrary, is more expressed in exosome-like vesicles, but is not present among the transferred proteins, thus strengthening our hypothesis (Figure 23C and Table VII). Further evidence of MVs participation in protein transport from CAFs to DU145 comes from vimentin. In particular, we found that vimentin profile in DU145 autoradiography (Figure 20D) is similar to that observed in MVs by Western blot analysis (Figure 23C). The various spots and bands displayed in both images may correspond to different glycosylated or phosphorylated forms of vimentin (Figures 20D and 23C).

Since MVs shed directly from the plasma membrane, we hypothesized that the selective enrichment of some proteins compared to other depends on their uneven spatial distribution within cytoplasm. Therefore, the specific selection of certain proteins may be due to their prevalent localization close to the plasma membrane regions where vesicles bud. The inclusion of mitochondrial proteins inside the vesicles (such as SOD-2, malate dehydrogenase and ATP synthase β subunit), instead, may occur during their mitochondrial-targeting signal peptide-mediated transport.

The functional role of the passage of these proteins has been confirmed by cell proliferation experiments (Figure 24). We found that DU145 increase their growth rate of about 8% when cultured in starvation medium supplemented only with MVs, suggesting that, besides to soluble factors-mediated cellular crosstalk, also membranous vesicles have a part in the pro-proliferative effect observed in tumor cells-CAFs coculture (Figure 15A-B). It is noteworthy that this effect could be lower compared to what could be achieved in the presence of a continuous production of vesicles by fibroblasts in coculture condition (Figure 15A-B).

In addition, recently Angelucci et al. showed that vimentin protein levels was clearly induced in the low-invasive MCF7 cell line cocultured with CAFs, and thus the epithelial mesenchymal transition is activated [648]. According to the observation that cells by capturing protein cargo contained within these vesicles can extend their transcriptome, it is possible that, besides the up-regulated gene-expression, fibroblasts-secreted MVs transfer vimentin to tumor cells by sustaining the increase
of its protein levels. Indeed, in DU145 autoradiography 5 of the 24 spots analyzed were identified as vimentin, which therefore is strongly represented (*Figure 20D and Table VII*).

In summary, these data reveal a novel role of fibroblasts in the context of the tumor microenvironment, which could represent a general property related to the trophic function of connective tissue. In fact, in the simplest hypothesis, fibroblasts support the survival and proliferation of neighbouring cells (which may be not only tumor cells, but also healthy cells) by releasing soluble growth factors and, simultaneously, transfer them vesicles laden of proteins and lipids. On one hand, growth factors stimulate cell growth and proliferation; on the other hand, protein and lipid cargo present into vesicles could increase the rate of mass accumulation to the lower limit necessary for cell division.
References

34. Harris CC. p53 tumor suppressor gene: from the basic research laboratory to the clinic—an integrated concept of malignant tumor progression. 2005 Nat Rev Cancer 5(12): a006676;
35. Levine AJ. p53, the cellular gatekeeper for growth and division. 1997 Oncogene 14(12): 1495-1502;
41. Volpert OV, Dameron KM and Bouch N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. 1997 Oncogene 14(12): 1495-1502;
44. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. 2005 Oncology 69(Suppl 3): 4-10;
48. Volpert OV, Dameron KM and Bouch N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. 1997 Oncogene 14(12): 1495-1502;
55. Berx G and van Roy F. Involvement of members of the cadherin superfamily in cancer. 2009 Cold Spring Harb Perspect Biol 1(6): a003129;
59. Thiem JM, Acolique H, Huang PY and Nieto MA. Epithelial-mesenchymal transitions in development and disease. 2009 Cell 139(5): 871-890;
63. Watnick RS. The role of the tumor microenvironment in regulating angiogenesis. 2012 Cold Spring Harb Perspect Med 2(12): a006676;
69. Tarin D and Croft CB. Ultradeformation features of wound healing in mouse skin. 1969 J Anat 105(Pt 1): 189-190;
74. Wiseman BS and Werb Z. Stromal effects on mammary gland development and breast cancer. 2002 Science 296(S570): 1046-1049;
80. Zeisberg M, Strutz F and Müller GA. Role of fibroblast activation in inducing interstitial fibrosis. 2000 J Nephrol 13(Suppl 3), S111-120;
References


120. Strutz F, Zeisberg M, Hemmerlein B, Sattler B, Hummel K, Becker V and Müller GA. Basic fibroblasts growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. 2000 Kidney Int 57(4): 1521-1538;


125. LeBedis C, Chen K, Fallavollita L, Boutros T, Brodt P. Peripheral lymph node stromal cells can promote growth and tumorigenicy of breast carcinoma cells through the release of IGF-1 and EGF. 2002 Int J Cancer 100(1): 2-8;


127. Chun TH, Hotary KB, Sabeh F, Saltiel AR, Allen ED and Weiss SJ. A pericellular collagenase directs the 3-dimensional development of white adipose tissue. 2006 Cell 125(3): 577-591;


130. Egeblad M, Rasch MG and Weaver VM. Dynamic interplay between the collagen scaffold and tumor evolution. 2010 Curr Opin Cell Biol 22(5): 697-706;


References


151. Erez N, Tritt M, Olson P and Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. 2010 Cancer Cell 17(2): 135-147;


159. Warburg OH. The Metabolism of Tumours: Investigations from the Kaiser Wilhelm Institute for Biology, Berlin-Dahlem (London, UK: Arnold Constable) 1930;


References

175. Hall AP. Review of the pericyte during angiogenesis and its role in cancer and diabetic retinopathy. 2006 Toxicol Pathol 34(6): 763-775;
infiltrating dendritic cells precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. 2004 Nat Med 10(9): 950-958;


207. Vaupel P and Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. 2004 Oncologist 9(Suppl 5): 4-9;


212. Honig CR. Modern cardiovascular physiology. 2nd ed. Boston (MA) and Toronto (ON, Canada): Little and Brown, 1988;


226. Pettersen EO and Lindmo T. Inhibition of cell-cycle progression by acute treatment with various degrees of hypoxia: modifications induced by low concentrations of misonidazole present during hypoxia. 1983 Br J Cancer 48(6): 809-817;
239. Laderoute KR, Grant TD, Murphy BJ and Sutherland RM. Enhanced epidermal growth factor receptor synthesis in human squamous carcinoma cells exposed to low levels of oxygen. 1992 Int J Cancer 52(3): 428-432;
References

278. McDonald PC, Winum YJ, Supuran CT and Dedhar S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. 2012 Oncotarget 3(1): 84-97;
279. Supuran CT and Scozzafava A. Applications of carbonic anhydrase inhibitors and activators in therapy. 2002 Exp Opin Ther Pat 12: 217-242;
280. Supuran CT and Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. 2000 Exp Opin Ther Patents 10: 575-600;
anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. 2011 Cancer Res 71(24): 7558-7567;


302. Potter CP and Harris AL. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. 2003 Br J Cancer 89(1): 2-7;


Watson PH, Chia SK, Wykoff CC, Han C, Leek RD, Sly WS, Gatter KC, Ratcliffe P and Harris AL. Carbonic anhydrase XII is a marker of good prognostic in invasive breast carcinoma. 2003 Br J Cancer 88(7): 1065-1070;


Ullah MS, Davies AJ and Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. 2006 J Biol Chem 281(14): 9030-9037;


References


363. Eble JA and Tuckwell DS. The alpha2beta1 integrin inhibitor rhodocetin binds to the A domain of the integrin alpha2 subunit proximal to the collagen-binding site. 2003 Biochem J 376(Pt 1): 77-85;


Vila JJ, Sharples RA, Lawson VA, Masters CL, Cappai R and Hill AF. Packaging of prions into exosomes is associated with a novel pathway of PrP processing. 2007 J Pathol 211(5): 582-590;

Masyuk AI, Huang BQ, Ward CJ, Gradilone SA, Banales JM, Masyuk TV, Radtke B, Splinter PL and LaRusso NF. Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia. 2010 Am J Physiol Gastrointest Liver Physiol 299(4): 990-999;

Smithers DW. No cell is an island. 1969 Br Med J 3(5673): 778;


Subra C, Laulagnier K, Perret B and Record M. Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies. 2007 Biochimie 89(2): 205-212;


Skog J, Wärdinger T, van Rijswijk Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichovsky AM and Breakfield XO. Glioblastoma microvesicles transport RNA and
proteins that promote tumour growth and provide diagnostic biomarkers. 2008 Nat Cell Biol 10(12): 1470-1476;
474. Savina A, Pader CM, Damiani MT and Colombo ML. Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. 2005 Traffic 6(2): 131-143;
487. Coccetti E, Racchetti G, Podini P and Meldolesi J. Enlargeosome traffic: exocytosis triggered by various signals is followed by endocytosis, membrane shedding or both. 2007 Traffic 8(6): 742-757;
511. Salzer U, Hinterdorfer P, Hunger U, Borken C and Prohaska R. Ca(++)-dependent vesicle release from erythrocytes involves stomatin-specific lipid rafts, synexin (annexinVII), and sorcin. 2002 Blood 99(7): 2569-2577;
525. Rozmyslowicz T, Majka M, Kijowski J, Murphy SL, Conover DO, Poncz M, Ratajczak J, Gaulton GN and Ratajczak MZ. Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV. 2003 AIDS 17(1): 33-42;


Pan BT and Johnstone RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. 1983 Cell 33(3): 967-978;


Rak J. Extracellular vesicles – biomarkers and effectors of the cellular interactome in cancer. 2013 Front Pharmacol 4: 21;


Hakulinen J, Junnikkala S, Sorsa T and Meri S. Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloprotease to a functionally active soluble form. 2004 Eur J Immunol 34(9): 2620-2629;


578. Fowlers RL, Riceo FR and Bobrove AM. Mononuclear cell tissue factor: cell of origin and requirements for activation. 1979 Blood 54(2): 359-370;


580. Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, Krymskaya OV and Ataullahkanov FI. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. 2007 Thromb Haemost 97(3): 425-434;


References

630. Shao ZM, Nguyen M and Barsky SH. Human breast carcinoma desmplasia is PDGF initiated. 2000 Oncogene 19(38): 4337-4345;
635. Robertson N, Potter C and Harris AL. Role of carbonic anhydrase IX in human tumour cell growth, survival, and invasion. 2004 Cancer Res, 64(17): 6160-6165;


645. Karagiannis GS, Poutahidis T, Erdman SE, Kirsch R, Riddell RH and Diamandis EP. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. 2012 Mol Cancer Res 10(11): 1403-1418;

